diff --git a/content/outputs/assay-protocols.md b/content/outputs/assay-protocols.md deleted file mode 100644 index 479633f86..000000000 --- a/content/outputs/assay-protocols.md +++ /dev/null @@ -1,12 +0,0 @@ ---- -weight: 95 -title: Assay Protocols -description: Assay protocols developed for ASAP Discovery programs -toc: true -draft: false ---- - -ASAP frequently needs to develop or scale its own biochemical assay protocols to drive discovery programs. -Whenever possible, we share these protocols through [protocols.io](http://protocols.io), an industry standard platform for sharing and annotating assay protocols. - -{{< assay-protocols >}} diff --git a/content/outputs/img/_index.md b/content/outputs/img/_index.md new file mode 100644 index 000000000..ca03031f1 --- /dev/null +++ b/content/outputs/img/_index.md @@ -0,0 +1,3 @@ +--- +headless: true +--- diff --git a/content/outputs/img/icons/README.md b/content/outputs/img/icons/README.md index 342dcf157..f866be329 100644 --- a/content/outputs/img/icons/README.md +++ b/content/outputs/img/icons/README.md @@ -1,3 +1,7 @@ +--- +draft: true +--- + # Icons from The Noun Project Icons are CC-BY from [The Noun Project](https://thenounproject.com/) diff --git a/content/outputs/molecules.md b/content/outputs/molecules.md index efef1f932..8daf0e84b 100644 --- a/content/outputs/molecules.md +++ b/content/outputs/molecules.md @@ -8,3 +8,12 @@ draft: false {{< molecules >}} +--- + +## ChEMBL Dataset Deposits + +ASAP Discovery deposits all assay data to [ChEMBL](https://www.ebi.ac.uk/chembl/), the open-access bioactivity database maintained by EMBL-EBI. +Below are all ASAP datasets available in ChEMBL, organized by category. Click on a dataset title to access the DOI, or click the ChEMBL ID to view the full dataset on ChEMBL. + +{{< chembl-datasets-table >}} + diff --git a/content/outputs/protocols.md b/content/outputs/protocols.md new file mode 100644 index 000000000..77c6a35df --- /dev/null +++ b/content/outputs/protocols.md @@ -0,0 +1,15 @@ +--- +weight: 95 +title: Protocols +description: All experimental protocols developed by ASAP Discovery +toc: false +draft: false +--- + +ASAP Discovery develops and shares experimental protocols to enable reproducibility and accelerate antiviral research. +Our protocols cover biochemical assays, crystallization, protein production, biophysical assays, ADMET studies, and antiviral screening. +All protocols are published through [protocols.io](https://protocols.io). + +Use the filters below to find protocols by category, target, or author. + +{{< protocols-table >}} diff --git a/data/outputs/TEPs/eva71-2A-protease.yaml b/data/outputs/TEPs/eva71-2A-protease.yaml index b337d4acd..81598e040 100644 --- a/data/outputs/TEPs/eva71-2A-protease.yaml +++ b/data/outputs/TEPs/eva71-2A-protease.yaml @@ -9,7 +9,7 @@ TEP: # ASAP program codename. From this list: # https://www.notion.so/asapdiscovery/Data-Core-11bd0c209eb44c409e532f00edf3f060?pvs=4#388f41b3676749889930c0898e04b89c program_code: ASAPPTBOAM - program_nickname: ASAP-EVA71-2APRO + program_nickname: ASAP-EVD68-2APRO # NCBI gene ID: Prefix https://www.ncbi.nlm.nih.gov/protein/ gene: JN544418.1 # Uniprot ID: @@ -207,3 +207,14 @@ TEP: - Martin Walsh - Daren Fearon - Frank von Delft + + - name: "Group deposition of Coxsackievirus A16 (G-10) 2A protease in complex with inhibitors from the ASAP AViDD centre" + id: eva71-2A-protease_inhibitor-screen-pdb-group-deposition + date: 2025-01-14 + type: pdb-group-deposition + url: https://www.rcsb.org/groups/summary/entry/G_1002329 + projects: [Project 2, Project 3] + cores: [Structural Biology Core] + description: | + Crystallographic structure of Coxsackievirus A16 (G-10) 2A protease in complex with inhibitors developed by the ASAP Discovery Consortium. + diff --git a/data/outputs/assay_protocols.yaml b/data/outputs/assay_protocols.yaml deleted file mode 100644 index 38f0327e6..000000000 --- a/data/outputs/assay_protocols.yaml +++ /dev/null @@ -1,59 +0,0 @@ -- id: MERS-CoV_Mpro_fluorescence-assay - permalink: http://asapdiscovery.org/outputs/assay-protocols/#MERS-CoV_Mpro_fluorescence-assay - name: MERS-CoV main protease (Mpro) activity fluorescence dose response biochemical assay - description: | - This biochemical assay measures the inhibition of protease activity of the MERS-CoV main viral protease (Mpro), also known as the 3C-like protease (3CLpro). - It is suitable for high-throughput dose-response measurements in a 384-well plates for supporting drug discovery efforts against this target. - links: - - name: assay protocol - url: https://www.protocols.io/view/mers-main-protease-mpro-fluorescence-dose-response-eq2ly7r1rlx9 - type: biochemical-assay-protocol - cores: [Biochemical Assay Core] - events: - - date: 2023-04-19 - description: draft v3 - -- id: SARS-CoV-2_Mpro_fluorescence-assay - permalink: http://asapdiscovery.org/outputs/assay-protocols/#SARS-CoV-2_Mpro_fluorescence-assay - name: SARS-CoV-2 main protease (Mpro) activity fluorescence dose response biochemical assay - description: | - This biochemical assay measures the inhibition of protease activity of the SARS-CoV-2 main viral protease (Mpro), also known as the 3C-like protease (3CLpro). - It is suitable for high-throughput dose-response measurements in a 384-well plates for supporting drug discovery efforts against this target. - links: - - name: assay protocol - url: https://www.protocols.io/view/sars-cov-2-mpro-fluorescence-dose-response-81wgbye9nvpk - type: biochemical-assay-protocol - cores: [Biochemical Assay Core] - events: - - date: 2024-04-28 - description: draft v4 - - date: 2023-04-28 - description: draft v3 - -- id: SARS-CoV-2_nsp3_TRFRET-assay - permalink: http://asapdiscovery.org/outputs/assay-protocols/#SARS-CoV-2_nsp3_TRFRET-assay - name: SARS-CoV-2 nsp3 Mac1 macrodomain TR-FRET peptide displacement biochemical assay - description: | - This is a TR-FRET peptide displacement assay to measure binding of small molecules to the active site of nsp3 Mac1 macrodomain - type: biochemical-assay-protocol - cores: [Biochemical Assay Core] - links: - - name: assay protocol - url: https://www.protocols.io/view/sars-cov-2-nsp3-mac1-macrodomain-tr-fret-peptide-d-eq2ly7r2mlx9/v2 - events: - - date: 2023-04-28 - description: draft v2 - -- id: flaviviruses_ns2ns3_fluorescence-assay - permalink: http://asapdiscovery.org/outputs/assay-protocols/#flaviviruses_ns2ns3_fluorescence-assay - name: Flaviviruses (West Nile, Zika, Dengue) NS2B/NS3 protease activity fluorescence dose response biochemical assay - description: | - This is a functional biochemical assay used to identify inhibitors of flavivirus (specifically West Nile, Zika, and Dengue) NS2B/NS3 protease activity. - type: biochemical-assay-protocol - cores: [Biochemical Assay Core] - links: - - name: assay protocol - url: https://www.protocols.io/view/flaviviruses-west-nile-zika-dengue-ns2b-ns3-fluore-q26g7yebkgwz/v2 - events: - - date: 2023-04-28 - description: draft v3 diff --git a/data/outputs/chembl_datasets.yaml b/data/outputs/chembl_datasets.yaml new file mode 100644 index 000000000..d69381805 --- /dev/null +++ b/data/outputs/chembl_datasets.yaml @@ -0,0 +1,281 @@ +# ChEMBL dataset deposits from ASAP Discovery + +- title: "DENV-1 NS2B-NS3 protease fluorescence dose response" + chembl_id: CHEMBL5604064 + doi_url: https://dx.doi.org/10.6019/CHEMBL5604064 + category: Biochemical + target: DENV-1 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes DENV-1 NS2B-NS3 protease fluorescence dose response data." + +- title: "DENV-2 NS2B-NS3 protease fluorescence dose response" + chembl_id: CHEMBL5604063 + doi_url: https://dx.doi.org/10.6019/CHEMBL5604063 + category: Biochemical + target: DENV-2 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes DENV-2 NS2B-NS3 protease fluorescence dose response data." + +- title: "DENV-2 NS2B-NS3 protease fluorescence single point" + chembl_id: CHEMBL5606460 + doi_url: https://dx.doi.org/10.6019/CHEMBL5606460 + category: Biochemical + target: DENV-2 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes DENV-2 NS2B-NS3 protease fluorescence single point data." + +- title: "DENV-3 NS2B-NS3 protease fluorescence dose response" + chembl_id: CHEMBL5604065 + doi_url: https://dx.doi.org/10.6019/CHEMBL5604065 + category: Biochemical + target: DENV-3 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes DENV-3 NS2B-NS3 protease fluorescence dose response data." + +- title: "DENV-4 NS2B-NS3 protease fluorescence dose response" + chembl_id: CHEMBL5604066 + doi_url: https://dx.doi.org/10.6019/CHEMBL5604066 + category: Biochemical + target: DENV-4 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes DENV-4 NS2B-NS3 protease fluorescence dose response data." + +- title: "SARS-CoV-2 nsp3 macrodomain dose response" + chembl_id: CHEMBL5441456 + doi_url: https://dx.doi.org/10.6019/CHEMBL5441456 + category: Biochemical + target: SARS-CoV-2 nsp3 Mac1 + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes SARS-CoV-2 nsp3 macrodomain dose response data." + +- title: "SARS-CoV-2 nsp3 macrodomain single point" + chembl_id: CHEMBL5442379 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442379 + category: Biochemical + target: SARS-CoV-2 nsp3 Mac1 + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes SARS-CoV-2 nsp3 macrodomain single point data." + +- title: "WNV NS2B-NS3 protease fluorescence dose response" + chembl_id: CHEMBL5604061 + doi_url: https://dx.doi.org/10.6019/CHEMBL5604061 + category: Biochemical + target: NS2B-NS3 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes WNV NS2B-NS3 protease fluorescence dose response data." + +- title: "WNV NS2B-NS3 protease fluorescence single point" + chembl_id: CHEMBL5606459 + doi_url: https://dx.doi.org/10.6019/CHEMBL5606459 + category: Biochemical + target: NS2B-NS3 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes WNV NS2B-NS3 protease fluorescence single point data." + +- title: "ZIKV NS2B-NS3 protease fluorescence dose response" + chembl_id: CHEMBL5604062 + doi_url: https://dx.doi.org/10.6019/CHEMBL5604062 + category: Biochemical + target: NS2B-NS3 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes ZIKV NS2B-NS3 protease fluorescence dose response data." + +- title: "ZIKV NS2B-NS3 protease fluorescence single point" + chembl_id: CHEMBL5606458 + doi_url: https://dx.doi.org/10.6019/CHEMBL5606458 + category: Biochemical + target: NS2B-NS3 + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes ZIKV NS2B-NS3 protease fluorescence single point data." + +- title: "In vitro antiviral effect" + chembl_id: CHEMBL5441381 + doi_url: https://dx.doi.org/10.6019/CHEMBL5441381 + category: Antiviral + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes antiviral effect data." + +- title: "In vitro antiviral effect" + chembl_id: CHEMBL5661943 + doi_url: https://dx.doi.org/10.6019/CHEMBL5661943 + category: Antiviral + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes antiviral effect data." + +- title: "In vitro cytotoxicity" + chembl_id: CHEMBL5441451 + doi_url: https://dx.doi.org/10.6019/CHEMBL5441451 + category: Antiviral + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes cytotoxicity data." + +- title: "In vitro cytotoxicity" + chembl_id: CHEMBL5661955 + doi_url: https://dx.doi.org/10.6019/CHEMBL5661955 + category: Antiviral + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes cytotoxicity data." + +- title: "In vitro CYP inhibition pooled" + chembl_id: CHEMBL5441445 + doi_url: https://dx.doi.org/10.6019/CHEMBL5441445 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes CYP inhibition data." + +- title: "In vitro LogD" + chembl_id: CHEMBL5442685 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442685 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro logD data." + +- title: "In vitro LogD" + chembl_id: CHEMBL5674854 + doi_url: https://dx.doi.org/10.6019/CHEMBL5674854 + category: ADMET + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro logD data." + +- title: "In vitro MDCK-MDR1 permeability" + chembl_id: CHEMBL5442303 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442303 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes permeability data." + +- title: "In vitro MDCK-MDR1 permeability" + chembl_id: CHEMBL5674852 + doi_url: https://dx.doi.org/10.6019/CHEMBL5674852 + category: ADMET + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes permeability data." + +- title: "In vitro cardiotoxicity" + chembl_id: CHEMBL5441442 + doi_url: https://dx.doi.org/10.6019/CHEMBL5441442 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes cardiotoxicity data." + +- title: "In vitro hepatocyte stability" + chembl_id: CHEMBL5442163 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442163 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro hepatocyte stability data." + +- title: "In vitro kinase profile" + chembl_id: CHEMBL5442741 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442741 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro kinase profiling data." + +- title: "In vitro liver microsomal stability" + chembl_id: CHEMBL5442168 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442168 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro liver microsomal stability data." + +- title: "In vitro liver microsomal stability" + chembl_id: CHEMBL5665440 + doi_url: https://dx.doi.org/10.6019/CHEMBL5665440 + category: ADMET + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro liver microsomal stability data." + +- title: "In vitro protein binding" + chembl_id: CHEMBL5442321 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442321 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes plasma protein binding data." + +- title: "In vitro protein binding" + chembl_id: CHEMBL5674856 + doi_url: https://dx.doi.org/10.6019/CHEMBL5674856 + category: ADMET + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes protein binding data." + +- title: "In vitro safety pharmacology profile" + chembl_id: CHEMBL5442334 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442334 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes in vitro safety pharmacology profile data." + +- title: "Solubility" + chembl_id: CHEMBL5442663 + doi_url: https://dx.doi.org/10.6019/CHEMBL5442663 + category: ADMET + target: General + date: 2024-12-01 + chembl_release: CHEMBL_35 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes solubility data." + +- title: "Solubility" + chembl_id: CHEMBL5674850 + doi_url: https://dx.doi.org/10.6019/CHEMBL5674850 + category: ADMET + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes solubility data." + +- title: "In vitro binding kinetics" + chembl_id: CHEMBL5598561 + doi_url: https://dx.doi.org/10.6019/CHEMBL5598561 + category: Biophysical + target: General + date: 2025-07-28 + chembl_release: CHEMBL_36 + description: "According to the assay cascade defined by the AI-driven Structure-enabled Antiviral Platform (ASAP, https://asapdiscovery.org) which contains assays and progression criteria used by the drug discovery program, this dataset includes binding kinetics data." + diff --git a/data/outputs/molecules.yaml b/data/outputs/molecules.yaml index c5fd56c02..93689677a 100644 --- a/data/outputs/molecules.yaml +++ b/data/outputs/molecules.yaml @@ -32,7 +32,11 @@ ASAP-SARS-COV-2-NSP3-MAC1: url: https://asapdiscovery.notion.site/SARS-COV-2-Macrodomain-Mac1-Inhibitor-Data-Release-26c94b98aff680a8908efe86bc5dbdb6 - name: biochemical assay protocol url: https://www.protocols.io/view/sars-cov-2-nsp3-mac1-macrodomain-tr-fret-peptide-d-eq2ly7r2mlx9/v2 - events: + - name: ChEMBL 35 database release + url: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_35/ + - name: ChEMBL 35 announcement + url: https://chembl.blogspot.com/2024/12/heres-nice-christmas-gift-chembl-35-is.html + events: - date: 2023-04-30 description: Initial public release of hit-to-lead biochemical assay data for 783 molecules. - date: 2023-11-07 @@ -49,6 +53,10 @@ ASAP-DENV-NS2B-NS3: url: https://asapdiscovery.notion.site/DENV2-NS2B-NS3-Potency-Data-26b94b98aff68032bffcd8c766f1685b - name: assay protocol url: https://www.protocols.io/view/flaviviruses-west-nile-zika-dengue-ns2b-ns3-fluore-q26g7yebkgwz/v1 + - name: ChEMBL 36 database release + url: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_36/ + - name: ChEMBL 36 announcement + url: https://chembl.blogspot.com/2025/09/chembl-36-is-out.html events: - date: 2023-04-30 description: Initial public release of covalent fragment screen and hit confirmation assay data for 652 molecules. @@ -64,6 +72,10 @@ ASAP-WNV-NS2B-NS3: url: https://asapdiscovery.notion.site/WNV-NS2B-NS3-Potency-Data-26b94b98aff6808584e1e061576b53ea - name: assay protocol url: https://www.protocols.io/view/flaviviruses-west-nile-zika-dengue-ns2b-ns3-fluore-q26g7yebkgwz/v1 + - name: ChEMBL 36 database release + url: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_36/ + - name: ChEMBL 36 announcement + url: https://chembl.blogspot.com/2025/09/chembl-36-is-out.html events: - date: 2023-04-30 description: Initial public release of covalent fragment screen and hit confirmation assay data for 646 molecules. @@ -79,6 +91,10 @@ ASAP-ZIKA-NS2B-NS3: url: https://asapdiscovery.notion.site/ZIKA-NS2B-NS3-Potency-Data-26b94b98aff680ee838dc23e8132c501?pvs=74 - name: assay protocol url: https://www.protocols.io/view/flaviviruses-west-nile-zika-dengue-ns2b-ns3-fluore-q26g7yebkgwz/v1 + - name: ChEMBL 36 database release + url: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_36/ + - name: ChEMBL 36 announcement + url: https://chembl.blogspot.com/2025/09/chembl-36-is-out.html events: - date: 2023-04-30 description: Initial public release of covalent fragment screen and hit confirmation assay data for 653 molecules. diff --git a/data/outputs/protocols.yaml b/data/outputs/protocols.yaml new file mode 100644 index 000000000..942375f3f --- /dev/null +++ b/data/outputs/protocols.yaml @@ -0,0 +1,1293 @@ +# Unified protocols database for ASAP Discovery +# All protocols with consistent tags for filtering + +# Biochemical Assay Protocols +- name: Assay for Screening of Compounds that Inhibit Enzymatic Activity of EV-A71 2Apro + url: https://www.protocols.io/view/assay-for-screening-of-compounds-that-inhibit-enzy-dsdq6a5w/v1 + category: Biochemical Assay + target: EV-A71 2A protease + author: Diana Alieksieieva + date: 2025-08-10 + version: v1 + description: "This protocol describes a biochemical assay used in screening to identify compounds that inhibit the enzymatic activity of the EV-A71 2A protease. Under standard conditions, the enzyme cleaves its substrate (DABCYL-RDKITTLGKFGQDE-EDANS), releasing the fluorogenic moiety EDANS, increasing fluoresc..." + cores: [Biochemical Assay Core] + +- name: Assay for screening of compounds that inhibit enzymatic activity of DENV-2 NS2B-NS3 protease + url: https://www.protocols.io/view/assay-for-screening-of-compounds-that-inhibit-enzy-dpc45iyw/v1 + category: Biochemical Assay + target: DENV NS2B-NS3 + author: Kateryna Horbatok + date: 2025-08-04 + version: v1 + description: "This protocol describes the enzymatic assay used to identify compounds that inhibit enzymatic activity of the dengue virus protease (DENV-2 NS2B-NS3 protease). Enzymatic assay is based on the conversion of substrate into product, which is used for quantification of enzyme activity. In case of usi..." + cores: [Biochemical Assay Core] + +- name: Assay for screening of compounds that inhibit enzymatic activity of ZIKV NS2B-NS3 protease + url: https://www.protocols.io/view/assay-for-screening-of-compounds-that-inhibit-enzy-dpse5nbe/v1 + category: Biochemical Assay + target: ZIKV NS2B-NS3 + author: Oleksandr Zhadovets + date: 2025-08-04 + version: v1 + description: "This protocol describes the enzymatic assay used to identify compounds that inhibit enzymatic activity of the dengue virus protease (ZIKV NS2B-NS3 protease). Enzymatic assay is based on the conversion of substrate into product, which is used for quantification of enzyme activity. In case of using..." + cores: [Biochemical Assay Core] + +- name: DENV NS2B-NS3 fluorescence single point screening assay + url: https://www.protocols.io/view/denv-ns2b-ns3-fluorescence-single-point-screening-dqz25x8e/v1 + category: Biochemical Assay + target: DENV NS2B-NS3 + author: Haim Barr + date: 2025-08-04 + version: v1 + description: "Purpose: performing single point test of selected compounds from screening libraries containing serine-targeting fragments and serine protease inhibitors against DENV NS2B-NS3 to find warheads and candidates for medicinal optimization General description: This protocol details the fluorescent ass..." + cores: [Biochemical Assay Core] + +- name: Enteroviruses (EV-D68/EV-A71) 3C and EVA71-2A proteases fluorescence single and dose response + url: https://www.protocols.io/view/enteroviruses-ev-d68-ev-a71-3c-and-eva71-2a-protea-dcy92xz6/v1 + category: Biochemical Assay + target: Enterovirus 3C/2A + author: Haim Barr + date: 2025-06-20 + version: v1 + description: "This is a functional, biochemical assay used to identify treatments for viral infectious diseases related to Enteroviruses infection, specifically EV-D68 3C, EV-A71 3C and EV-A71 2A proteases. In this current version we have added the Addgene id. Utilizing a direct enzyme activity measurement me..." + cores: [Biochemical Assay Core] + +- name: Flaviviruses (West Nile, Zika, Dengue serotypes 1-4) NS2B-NS3 protease fluorescence dose response and single point assay + url: https://www.protocols.io/view/flaviviruses-west-nile-zika-dengue-serotypes-1-4-n-g2m3byc8p/v4 + category: Biochemical Assay + target: Flavivirus NS2B-NS3 + author: Haim Barr + date: 2025-06-20 + version: v4 + description: "This is a functional, biochemical assay used to identify treatments for viral infectious diseases related to Flavivirus infection, (specifically West Nile, Zika, and Dengue) and targets the conserved NS2B-NS3 protein. In this current version, we added the Addgne id. Utilizing a direct enzyme act..." + cores: [Biochemical Assay Core] + +- name: Fluorescence assay for Enterovirus A71 3C protease activity measurement for screening against antiviral molecules + url: https://www.protocols.io/view/fluorescence-assay-for-enterovirus-a71-3c-protease-g2nubydex/v3 + category: Biochemical Assay + target: EV-A71 3C protease + author: Charline Giroud + date: 2025-06-04 + version: v3 + description: "This protocol details the fluorescence assay for Enterovirus A71 (EV-A71) 3C protease activity measurement. This method is intended to measure the activity of viral proteases by using a specific labelled-peptide that allows the detection of the cleaved product. The substrate contains the cleavage..." + cores: [Biochemical Assay Core] + +- name: Fluorescence assay for Enterovirus coxsackievirus A16 2A protease activity measurement + url: https://www.protocols.io/view/fluorescence-assay-for-enterovirus-coxsackievirus-dzkp74vn/v2 + category: Biochemical Assay + target: CVA16 2A protease + author: Charline Giroud + date: 2025-05-21 + version: v2 + description: "This protocol details the fluorescence assay for Enterovirus coxsackievirus A16 (CVA16) 2A protease activity measurement. This method is intended to measure the activity of viral proteases by using a specific labelled-peptide that allows the detection of the cleaved product. The substrate contain..." + cores: [Biochemical Assay Core] + +- name: Fluorescence assay for MERS-CoV Mpro protease activity measurement for screening against antiviral molecules + url: https://www.protocols.io/view/fluorescence-assay-for-mers-cov-mpro-protease-acti-dzan72de/v2 + category: Biochemical Assay + target: MERS-CoV Mpro + author: Charline Giroud + date: 2025-06-20 + version: v2 + description: "This protocol details the fluorescence assay for MERS-CoV Mpro protease activity measurement. This method is intended to measure the activity of viral proteases by using a specific labelled peptide that allows the detection of the cleaved product. The substrate contains the cleavage-sequence spec..." + cores: [Biochemical Assay Core] + +- name: Fluorescence assay of EV-D68 3C protease activity measurement for screening against antiviral molecules + url: https://www.protocols.io/view/fluorescence-assay-of-ev-d68-3c-protease-activity-g2nsbydef/v3 + category: Biochemical Assay + target: EV-D68 3C protease + author: Charline Giroud + date: 2025-06-04 + version: v3 + description: "This protocol details the fluorescence assay for Enterovirus D68 (EV-D68) 3C protease activity measurement. This method is intended to measure the activity of viral proteases by using a specific labelled-peptide that allows the detection of the cleaved product. The substrate contains the cleavage..." + cores: [Biochemical Assay Core] + +- name: MERS-CoV Mpro fluorescence dose response for antiviral testing + url: https://www.protocols.io/view/mers-cov-mpro-fluorescence-dose-response-for-antiv-cuxjwxkn/v5 + category: Biochemical Assay + target: MERS-CoV Mpro + author: Haim Barr + date: 2025-06-08 + version: v5 + description: "This is a functional, biochemical assay used to identify treatments for viral infectious disease in MERS-CoV 3C-like protease. Utilizing a direct enzyme activity measurement method, the experiment was performed in a 384-well plate reading the fluorescence intensity. This assay tested the mode o..." + cores: [Biochemical Assay Core] + +- name: SARS-CoV-2 Mpro fluorescence dose response + url: https://www.protocols.io/view/sars-cov-2-mpro-fluorescence-dose-response-g2nnbyddf/v5 + category: Biochemical Assay + target: SARS-CoV-2 Mpro + author: Haim Barr + date: 2025-06-20 + version: v5 + description: "This is a functional, biochemical assay used to identify treatments for viral infectious disease that target SARS-COV-2 Main Protease (MPro). In this version we added the protein expression and purification protocol together with the Addgene ID of the plasmid used. + +Utilizing a direct enzyme acti..." + cores: [Biochemical Assay Core] + +- name: SARS-CoV-2 nsp3 macrodomain Time-Resolved FRET peptide displacement assay + url: https://www.protocols.io/view/sars-cov-2-nsp3-macrodomain-time-resolved-fret-pep-g2vhbye37/v5 + category: Biochemical Assay + target: SARS-CoV-2 nsp3 macrodomain + author: Haim Barr + date: 2025-08-09 + version: v5 + description: "This protocol details the Time-Resolved FRET (TR-FRET) assay for SARS-CoV-2 nsp3 (non-structural protein 3) macrodomain (Mac1) binding of adenosine diphosphate (ADP)–ribosylated (ADPr) peptide. This method measures the affinity of Mac1 to its potential inhibitors by using a specific ADPr-modified..." + cores: [Biochemical Assay Core] + +- name: "Screening compounds that inhibit SARS-CoV-2 nsp3 macrodomain: ADP-Ribose quantification by LC/MS-MS" + url: https://www.protocols.io/view/screening-compounds-that-inhibit-sars-cov-2-nsp3-m-dmd54286/v1 + category: Biochemical Assay + target: SARS-CoV-2 nsp3 macrodomain + author: Noa Lahav + date: 2025-06-20 + version: v1 + description: "Functional biochemical assay to identify treatments for viral infectious disease that targets SARS-CoV-2 nsp3 macrodomain (MAC1). Utilizing Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) analysis, MAC1 ability to hydrolyze αNAD+ in the presence of potential inhibitors was me..." + cores: [Biochemical Assay Core] + +- name: WNV NS2B-NS3 fluorescence single point + url: https://www.protocols.io/view/wnv-ns2b-ns3-fluorescence-single-point-dq3v5yn6/v1 + category: Biochemical Assay + target: WNV NS2B-NS3 + author: Haim Barr + date: 2025-08-04 + version: v1 + description: "Purpose: performing single point test of selected compounds from screening experiment libraries containing serine-targeting fragments and serine protease inhibitors against WNV NS2B/NS3 to find warheads and candidates for medicinal optimization General description: This protocol details the fluor..." + cores: [Biochemical Assay Core] + +- name: ZIKV NS2B-NS3 fluorescence single point screening assay + url: https://www.protocols.io/view/zikv-ns2b-ns3-fluorescence-single-point-screening-dq3t5ynn/v1 + category: Biochemical Assay + target: ZIKV NS2B-NS3 + author: Haim Barr + date: 2025-08-21 + version: v1 + description: "Purpose: performing single point test of selected compounds from screening libraries containing serine-targeting fragments and serine protease inhibitors against ZIKV NS2B-NS3 to find warheads and candidates for medicinal optimization General description: This protocol details the fluorescent ass..." + cores: [Biochemical Assay Core] + +- name: ZIKV NS2B-NS3 protease dose response screening assay + url: https://www.protocols.io/view/zikv-ns2b-ns3-protease-dose-response-screening-ass-dq3w5ype/v1 + category: Biochemical Assay + target: ZIKV NS2B-NS3 + author: Haim Barr + date: 2025-08-04 + version: v1 + description: "Purpose: performing dose-response test of selected compounds from screening experiments against ZIKV NS2B-NS3 to confirm efficacy General description: This protocol details the fluorescent assays for ZIKV NS2B-NS3 cleavage of substrate Bz-Nle-KRR-AMC peptide. This method measures the fluorescence..." + cores: [Biochemical Assay Core] + +# Crystallization Protocols +- name: Co-crystallisation protocol for SARS-CoV-2 nsp3 macrodomain in P1 21 1 with ligands + url: https://www.protocols.io/view/co-crystallisation-protocol-for-sars-cov-2-nsp3-ma-djdp4i5n/v1 + category: Crystallization + target: SARS-CoV-2 nsp3 macrodomain + author: Jasmin Aschenbrenner + date: 2024-08-19 + version: v1 + description: "The COVID-19 pandemic has demonstrated the need for novel therapeutic interventions and improved pandemic preparedness strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This protocol details an optimized crystallization method for the SARS-CoV-2 nsp3 macrodomain, a ..." + cores: [Structural Biology Core] + +- name: "Crystal structure of Enterovirus A71 2A protease mutant C110A containing VP1-2A junction in the active site apo structure (C1 PDB: 9FGO) used for fragment screen and compound soaking" + url: https://www.protocols.io/view/crystal-structure-of-enterovirus-a71-2a-protease-m-d44n8yve/v1 + category: Crystallization + target: EV-A71 2A protease + author: Xiaomin Ni + date: 2025-07-25 + version: v1 + description: "This protocol describes the crystallization of Enterovirus 71 (EV-71) 2A protease mutant C110A containing the VP1-2A junction in the active site. The crystals form within 12-24 hours using a crystallization screen composed of 1.8M NaCl and 15% ethanol. The crystal structure was determined using X..." + cores: [Structural Biology Core] + +- name: Crystallisation of Enterovirus D68 3C protease + url: https://www.protocols.io/view/crystallisation-of-enterovirus-d68-3c-protease-g2qqbydvx/v2 + category: Crystallization + target: EV-D68 3C protease + author: Ryan Lithgo + date: 2025-06-05 + version: v2 + description: "The development of effective broad-spectrum antivirals forms an important part of preparing for future pandemics. A cause for concern is the currently emerging pathogen Enterovirus D68 (EV-D68) which primarily spreads through respiratory routes causing mostly mild to severe respiratory illness bu..." + cores: [Structural Biology Core] + +- name: Crystallisation of Enterovirus D68 3C protease apo structure and fragment screen in space group P212121 (PDB code 8CNX) + url: https://www.protocols.io/view/crystallisation-of-enterovirus-d68-3c-protease-apo-dy9z7z76/v2 + category: Crystallization + target: EV-D68 3C protease + author: Ryan Lithgo + date: 2025-04-25 + version: v2 + description: "The crystallization protocol and buffer conditions used to obtain Enterovirus D68 3C protease crystals. The crystal structure was depostited to RCSB PDB with code 8CNX. In this new version we added the Addgene ID and the protein expression and purification protocol. This construct gave us a crys..." + cores: [Structural Biology Core] + +- name: Crystallisation of Enterovirus D68 3C protease in space group P21 used for follow up compounds + url: https://www.protocols.io/view/crystallisation-of-enterovirus-d68-3c-protease-in-drkd54s6/v2 + category: Crystallization + target: EV-D68 3C protease + author: Ryan Lithgo + date: 2025-04-25 + version: v2 + description: "The development of effective broad-spectrum antivirals forms an important part of preparing for future pandemics. A current cause for concern is the emerging pathogen Enterovirus D68 (EV-D68), which primarily spreads through respiratory routes. While it mostly causes mild to severe respiratory il..." + cores: [Structural Biology Core] + +- name: Crystallisation of Enterovirus coxsackievirus A16 2A protease + url: https://www.protocols.io/view/crystallisation-of-enterovirus-coxsackievirus-a16-dgax3sfn/v1 + category: Crystallization + target: CVA16 2A protease + author: Ryan Lithgo + date: 2024-10-02 + version: v1 + description: "Picornaviridae coxsackievirus A16 is the causative agent of paediatric hand-foot-and-mouth disease, and a target for pandemic preparedness due to the risk of higher order complications in a large-scale outbreak. The 2A protease of the virus is responsible for self-cleavage from the poly protein, ..." + cores: [Structural Biology Core] + +- name: Crystallisation of Enterovirus coxsackievirus A16 2A protease in space group C2 used for apo, fragment screen and follow compounds (PDB 8POA) + url: https://www.protocols.io/view/crystallisation-of-enterovirus-coxsackievirus-a16-fafxbibpp/v2 + category: Crystallization + target: CVA16 2A protease + author: Ryan Lithgo + date: 2025-04-25 + version: v2 + description: "Picornaviridae coxsackievirus A16 is the causative agent of paediatric hand-foot-and-mouth disease, and a target for pandemic preparedness due to the risk of higher order complications in a large-scale outbreak. The 2A protease of the virus is responsible for self-cleavage from the poly protein, ..." + cores: [Structural Biology Core] + +- name: Crystallisation of MERS-CoV Mpro in C2221 used for compound soaking + url: https://www.protocols.io/view/crystallisation-of-mers-cov-mpro-in-c2221-used-for-d4hn8t5e/v2 + category: Crystallization + target: MERS-CoV Mpro + author: Blake Balcomb + date: 2025-05-13 + version: v2 + description: "The COVID-19 pandemic has highlighted the need to identify novel therapeutic interventions and strategies for pandemic preparedness. Other than Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), there are several human coronaviruses that are of pandemic concern, these include SARS-CoV ..." + cores: [Structural Biology Core] + +- name: Crystallisation of SARS-CoV-2 C terminal nucleocapsid protein for fragment screening and compound soaking + url: https://www.protocols.io/view/crystallisation-of-sars-cov-2-c-terminal-nucleocap-g73gbzqjx/v2 + category: Crystallization + target: SARS-CoV-2 N protein + author: Peter Marples + date: 2025-10-16 + version: v2 + description: "The crystallization protocol and buffer conditions used to obtain reproducible SARS CoV-2 Nucleocapsid crystals suitable for XChem fragment screening. In this new version we added the Addgene id, together with the expression and purification protocol. We also added the solvent tolerance test and ..." + cores: [Structural Biology Core] + +- name: Crystallisation of SARS-CoV-2 MPro in P212121 for compound soaking + url: https://www.protocols.io/view/crystallisation-of-sars-cov-2-mpro-in-p212121-for-d4m68u9e/v2 + category: Crystallization + target: SARS-CoV-2 Mpro + author: Blake Balcomb + date: 2025-05-13 + version: v2 + description: "The COVID-19 pandemic has highlighted the need to identify novel therapeutic interventions and strategies for pandemic preparedness against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This protocol outlines the crystallization protocol and buffer conditions used to obtain reprod..." + cores: [Structural Biology Core] + +- name: "Crystallisation of West Nile virus NS2B-NS3 protease in P64 (PDB ID: 8CO8)" + url: https://www.protocols.io/view/crystallisation-of-west-nile-virus-ns2b-ns3-protea-g2p9bydr7/v2 + category: Crystallization + target: WNV NS2B-NS3 + author: Blake Balcomb + date: 2025-06-05 + version: v2 + description: "West Nile virus NS2B-NS3 innactive fusion protease was crystallized using vapor diffusion in Morpheus screen conditions at pH 8.5. Hexagonal rod-shaped crystals grew to ~50 μm in length after 14 days at 20°C. The crystals belonged to space group P64 and diffracted to 1.91 Å resolution at Diamond ..." + cores: [Structural Biology Core] + +- name: Crystallisation of Zika NS5 RdRp + url: https://www.protocols.io/view/crystallisation-of-zika-ns5-rdrp-dnh45b8w/v1 + category: Crystallization + target: ZIKV NS5 RdRp + author: Anu V. Chandran + date: 2024-10-02 + version: v1 + description: "The main aim of this work was to identify small molecules that bind Zika NS5 RdRp (catalytic RNA-dependent RNA polymerase domain) through X-ray fragment-based screening. The Zika NS5 RDRP domain was cloned, expressed, purified, and crystallised. Suitable crystals for fragment screening were prod..." + cores: [Structural Biology Core] + +- name: Crystallisation protocol for SARS-CoV-2 nsp3 macrodomain in P1 21 1 + url: https://www.protocols.io/view/crystallisation-protocol-for-sars-cov-2-nsp3-macro-df6a3rae/v1 + category: Crystallization + target: SARS-CoV-2 nsp3 macrodomain + author: Jasmin Aschenbrenner + date: 2024-08-19 + version: v1 + description: "The COVID-19 pandemic has demonstrated the need for novel therapeutic interventions and improved pandemic preparedness strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This protocol details an optimized crystallization method for the SARS-CoV-2 nsp3 macrodomain, a ..." + cores: [Structural Biology Core] + +- name: Crystallisation protocol for SARS-CoV-2 nsp3 macrodomain in P43 + url: https://www.protocols.io/view/crystallisation-protocol-for-sars-cov-2-nsp3-macro-g2q3bydyp/v2 + category: Crystallization + target: SARS-CoV-2 nsp3 macrodomain + author: Jasmin Aschenbrenner + date: 2025-08-21 + version: v2 + description: "The COVID-19 pandemic has demonstrated the need for novel therapeutic interventions and improved pandemic preparedness strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This protocol details an optimized crystallization method for the SARS-CoV-2 nsp3 macrodomain, a ..." + cores: [Structural Biology Core] + +- name: Crystallization of Enterovirus A71 3C protease in C2221 apo structure (PDB 8CNY) + url: https://www.protocols.io/view/crystallization-of-enterovirus-a71-3c-protease-in-fahkbib4x/v2 + category: Crystallization + target: EV-A71 3C protease + author: Ryan Lithgo + date: 2025-04-30 + version: v2 + description: "The crystallization protocol and buffer conditions used to obtain Enterovirus A71 3C protease crystals. The crystal structure was depostited to RCSB PDB with code 8CNY. In this version we added: protein production, solvent tolerance test protocols and the Addgene ID of the contruct used." + cores: [Structural Biology Core] + +- name: Crystallization of MERS-CoV Mpro + url: https://www.protocols.io/view/crystallization-of-mers-cov-mpro-dcr52v86/v1 + category: Crystallization + target: MERS-CoV Mpro + author: Blake Balcomb + date: 2024-04-26 + version: v1 + description: "The COVID-19 pandemic has highlighted the need to identify novel therapeutic interventions and strategies for pandemic preparedness. Other than Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), there are several human coronaviruses that are of pandemic concern, these include SARS-CoV ..." + cores: [Structural Biology Core] + +- name: Crystallization of SARS-CoV-2 Mpro + url: https://www.protocols.io/view/crystallization-of-sars-cov-2-mpro-dcr42v8w/v1 + category: Crystallization + target: SARS-CoV-2 Mpro + author: Blake Balcomb + date: 2024-04-26 + version: v1 + description: "The COVID-19 pandemic has highlighted the need to identify novel therapeutic interventions and strategies for pandemic preparedness against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This protocol outlines the crystallization protocol and buffer conditions used to obtain reprod..." + cores: [Structural Biology Core] + +- name: Crystallization of SARS-CoV-2 N Protein + url: https://www.protocols.io/view/crystallization-of-sars-cov-2-n-protein-dcr32v8n/v1 + category: Crystallization + target: SARS-CoV-2 N protein + author: Peter Marples + date: 2024-04-26 + version: v1 + description: "The crystallization protocol and buffer conditions used to obtain reproducible SARS C0V-2 Nucelocapsid crystals suitable for XChem fragment screening." + cores: [Structural Biology Core] + +- name: Crystallization of SARS-CoV-2 nsp15 NendoU + url: https://www.protocols.io/view/crystallization-of-sars-cov-2-nsp15-nendou-dcr22v8e/v1 + category: Crystallization + target: SARS-CoV-2 nsp15 + author: Peter Marples + date: 2024-04-26 + version: v1 + description: "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). The NSP15 endoribonuclease enzyme, known as NendoU, is highly conserved and plays a critical role in the ability of the virus to evade the immune system. NendoU is a promisi..." + cores: [Structural Biology Core] + +- name: Crystallization of Zika NS5 RdRp + url: https://www.protocols.io/view/crystallization-of-zika-ns5-rdrp-dcrx2v7n/v1 + category: Crystallization + target: ZIKV NS5 RdRp + author: Anu V. Chandran + date: 2024-04-26 + version: v1 + description: "The main aim of this work was to identify small molecules that bind Zika NS5 RdRp (catalytic RNA-dependent RNA polymerase domain) through X-ray fragment-based screening. The Zika NS5 RDRP domain was cloned, expressed, purified, and crystallised. Suitable crystals for fragment screening were prod..." + cores: [Structural Biology Core] + +- name: "Crystallization of Zika virus NS2B-NS3 protease (closed conformation in space group P4322 | PDB ID: 8PN6)" + url: https://www.protocols.io/view/crystallization-of-zika-virus-ns2b-ns3-protease-cl-dqyy5xxw/v2 + category: Crystallization + target: ZIKV NS2B-NS3 + author: Xiaomin Ni + date: 2025-04-17 + version: v2 + description: "Zika virus (ZIKV) NS3 protease with its NS2B cofactor is essential for the cleavage of Zika polyprotein precursor into individual structural and non-structural proteins and is therefore an attractive drug target. We optimized a robust crystal system of co-expressed NS3 protease with its NS2B cof..." + cores: [Structural Biology Core] + +- name: Crystallization of Zika virus NS3 helicase PDB + url: https://www.protocols.io/view/crystallization-of-zika-virus-ns3-helicase-pdb-g3p3bymqp/v2 + category: Crystallization + target: ZIKV NS3 helicase + author: Andre Schutzer de Godoy + date: 2025-07-25 + version: v2 + description: "The crystallization protocol and buffer conditions used to obtain Zika NS3 helicase crystals suitable for XChem fragment screening. The Zika virus (ZIKV), discovered in Africa in 1947, swiftly spread across continents, causing significant concern due to its recent association with microcephaly in..." + cores: [Structural Biology Core] + +- name: Diamond XChem Seeding Protocol + url: https://www.protocols.io/view/diamond-xchem-seeding-protocol-c23kygkw/v1 + category: Crystallization + target: General + author: Peter Marples + date: 2023-12-19 + version: v1 + description: "The use of seeding in protein crystallisation is a highly effective method for increasing the quantity of usable crystals from a single plate and can be crucial for obtaining crystals in a highly reproducible manner. Even crystallisation experiments which did not previously require seeding can b..." + cores: [Structural Biology Core] + +- name: "READDI protocol: Crystallisation of CHIKV nsP3 macrodomain" + url: https://www.protocols.io/view/readdi-protocol-crystallisation-of-chikv-nsp3-macr-dcr62v9e/v1 + category: Crystallization + target: CHIKV nsP3 macrodomain + author: Jasmin Aschenbrenner + date: 2024-07-02 + version: v1 + description: "Chikungunya virus (CHIKV) causes severe fever, rash and debilitating joint pain that can last for months or even years. Millions of people have been infected with CHIKV, mostly in low- and middle-income countries, and the virus continues to spread into new areas due to the geographical expansion ..." + cores: [Structural Biology Core] + +- name: "READDI protocol: Crystallisation of CHIKV nsP3 macrodomain" + url: https://www.protocols.io/view/readdi-protocol-crystallisation-of-chikv-nsp3-macr-dnxp5fmn/v2 + category: Crystallization + target: CHIKV nsP3 macrodomain + author: Jasmin Aschenbrenner + date: 2024-10-07 + version: v2 + description: "The crystallization protocol and buffer conditions used to obtain reproducible Chikungunya Virus NS3 macrodomain crystals suitable for XChem fragment screening." + cores: [Structural Biology Core] + +- name: "READDI protocol: Crystallisation of Dengue NS5 RdRp in I222" + url: https://www.protocols.io/view/readdi-protocol-crystallisation-of-dengue-ns5-rdrp-dyp87vrw/v1 + category: Crystallization + target: DENV NS5 RdRp + author: Jasmin Aschenbrenner + date: 2025-03-10 + version: v1 + description: "The crystallisation protocol and buffer conditions used to obtain reproducible Dengue virus serotype 2 RNA-dependent RNA polymerase crystals in I222 suitable for XChem fragment screening." + cores: [Structural Biology Core] + +- name: XChem crystallographic fragment screening + url: https://www.protocols.io/view/xchem-crystallographic-fragment-screening-dhxj37kn/v1 + category: Crystallization + target: General + author: Peter Marples + date: 2025-02-18 + version: v1 + description: "The XChem Facility at Diamond Light Source provides routine, large scale crystal graphic fragment screening, supporting the entire crystal to deposition process. X-ray crystallography is an essential part to the FBDD toolkit. It is sensitive enough to identify weak binders and directly yields str..." + cores: [Structural Biology Core] + +- name: XChem solvent test + url: https://www.protocols.io/view/xchem-solvent-test-dcpy2vpw/v1 + category: Crystallization + target: General + author: Peter Marples + date: 2025-02-18 + version: v1 + description: "The XChem Facility at Diamond Light Source provides routine, large scale crystal graphic fragment screening, supporting the entire crystal to deposition process. X-ray crystallography is an essential part to the FBDD toolkit. It is sensitive enough to identify weak binders and directly yields str..." + cores: [Structural Biology Core] + +# Protein Production Protocols +- name: DENV2 NS2B-NS3 protease co-expression construct small scale expression and purification protocol + url: https://www.protocols.io/view/denv2-ns2b-ns3-protease-co-expression-construct-sm-dfdm3i46/v3 + category: Protein Production + target: DENV NS2B-NS3 + author: Korvus Wang + date: 2024-06-10 + version: v3 + description: "This protocol details the co-expression and purification of DENV2 NS2B-NS3 protease coexpression construct bearing a N-terminal His-GST tag at small scale (<6L)." + cores: [Structural Biology Core] + +- name: "Dengue Virus Serotype 2 NS2B-NS3 protease fusion protein Avi-tagged (Biotinylated) protein expression and purification: large scale 1 L cultures" + url: https://www.protocols.io/view/dengue-virus-serotype-2-ns2b-ns3-protease-fusion-p-d4i68uhe/v1 + category: Protein Production + target: DENV + author: Michael Fairhead + date: 2025-04-15 + version: v1 + description: "This protocol details the expression and purification of Dengue Virus Serotype 2 NS2B-NS3 protease fusion protein with a AviTag (biotinylation tag) for biophysical assay at a 1 L culture scale. Recombinant proteins are expressed in Escherichia coli using the autoinduction method and then purified..." + cores: [Structural Biology Core] + +- name: Dengue virus serotype 1 NS2B-NS3 protease fusion construct small scale expression and purification protocol + url: https://www.protocols.io/view/dengue-virus-serotype-1-ns2b-ns3-protease-fusion-c-g2m5byc87/v3 + category: Protein Production + target: DENV NS2B-NS3 + author: Korvus Wang + date: 2025-06-04 + version: v3 + description: "This protocol details the co-expression and purification of Dengue virus serotype 1 NS2B-NS3 protease fusion construct bearing a N-terminal His-StrepII tag at small scale (<6L)." + cores: [Structural Biology Core] + +- name: Dengue virus serotype 2 NS2B-NS3 protease fusion construct small scale expression and purification for biophysical and biochemical assays protocol + url: https://www.protocols.io/view/dengue-virus-serotype-2-ns2b-ns3-protease-fusion-c-dzqt75wn/v2 + category: Protein Production + target: DENV NS2B-NS3 + author: Korvus Wang + date: 2025-08-28 + version: v2 + description: "This protocol details the co-expression and purification of Dengue virus serotype 2 NS2B-NS3 protease fusion construct bearing a N-terminal His-StrepII tag at small scale (<6L). The final product does not have its affinity tags removed, and is catalytically active. Final product is suitable for b..." + cores: [Structural Biology Core] + +- name: Dengue virus serotype 2 NS2B-NS3 protease fusion construct small scale expression and purification protocol + url: https://www.protocols.io/view/dengue-virus-serotype-2-ns2b-ns3-protease-fusion-c-gy2ibxycf/v3 + category: Protein Production + target: DENV NS2B-NS3 + author: Korvus Wang + date: 2025-06-04 + version: v3 + description: "This protocol details the co-expression and purification of Dengue virus serotype 2 NS2B-NS3 protease fusion construct bearing a N-terminal His-StrepII tag at small scale (<6L). This protocol produces catalytically active enzyme suitable for biochemical assays. In this version we added the Addgen..." + cores: [Structural Biology Core] + +- name: "Dengue virus serotype 3 NS2B-NS3 protease fusion construct using parallel rapid protein expression and purification: 100 mL cultures" + url: https://www.protocols.io/view/dengue-virus-serotype-3-ns2b-ns3-protease-fusion-g2nibydcf/v3 + category: Protein Production + target: DENV NS2B-NS3 + author: Michael Fairhead + date: 2025-06-04 + version: v3 + description: "This protocol details the small scale (100mL) expression and purification of Dengue virus serotype 3 NS2B-NS3 protease fusion constructs using the parallel rapid protein expression and purification (PREPX) method. Recombinant proteins are expressed in Escherichia coli using the autoinduction meth..." + cores: [Structural Biology Core] + +- name: "Dengue virus serotype 4 NS2B-NS3 protease fusion construct: 100 mL cultures" + url: https://www.protocols.io/view/dengue-virus-serotype-4-ns2b-ns3-protease-fusion-c-g2njbydcp/v2 + category: Protein Production + target: DENV NS2B-NS3 + author: Michael Fairhead + date: 2025-06-04 + version: v2 + description: "This protocol details the small scale (100 mL) expression and purification of Dengue virus serotype 4 (DENV-4) NS2B-NS3 protease fusion constructs using the parallel rapid expression and purification (PREPX) method. Recombinant proteins are expressed in Escherichia coli using the autoinduction m..." + cores: [Structural Biology Core] + +- name: Enterovirus A71 3C protease large scale purification protocol + url: https://www.protocols.io/view/enterovirus-a71-3c-protease-large-scale-purificati-dfpx3mpn/v1 + category: Protein Production + target: EV-A71 3C protease + author: Korvus Wang + date: 2025-07-29 + version: v1 + description: "This protocol details the expression and purification of enterovirus A71 3C protease construct bearing a C-terminal His-tag at large scale (>6L)" + cores: [Structural Biology Core] + +- name: Enterovirus A71 3C protease small scale expression and purification protocol + url: https://www.protocols.io/view/enterovirus-a71-3c-protease-small-scale-expressio-dfps3mne/v1 + category: Protein Production + target: EV-A71 3C protease + author: Korvus Wang + date: 2025-04-23 + version: v1 + description: "This protocol details the expression and purification of enterovirus A71 3C protease construct bearing a C-terminal His-tag at small scale (<6L)." + cores: [Structural Biology Core] + +- name: Enterovirus D68 3C protease large scale purification protocol + url: https://www.protocols.io/view/enterovirus-d68-3c-protease-large-scale-purificati-dfpz3mp6/v2 + category: Protein Production + target: EV-D68 3C protease + author: Korvus Wang + date: 2025-07-29 + version: v2 + description: "This protocol details the expression and purification of enterovirus D68 3C protease construct bearing a C-terminal His-tag at large scale (>6L)" + cores: [Structural Biology Core] + +- name: Enterovirus D68 3C protease small scale expression and purification protocol + url: https://www.protocols.io/view/enterovirus-d68-3c-protease-small-scale-expressio-dzkg74tw/v2 + category: Protein Production + target: EV-D68 3C protease + author: Korvus Wang + date: 2025-04-22 + version: v2 + description: "This protocol details the expression and purification of enterovirus D68 3C protease construct bearing a C-terminal His-tag at small scale (<6L)." + cores: [Structural Biology Core] + +- name: Enterovirus coxsackievirus A16 2A protease small scale expression and purification protocol + url: https://www.protocols.io/view/enterovirus-coxsackievirus-a16-2a-protease-small-s-dxiv7ke6/v3 + category: Protein Production + target: CVA16 2A protease + author: Korvus Wang + date: 2025-04-22 + version: v3 + description: "This protocol details the expression and purification of coxsackievirus A16 2A protease construct bearing a N-terminal His-SUMO tag at small scale (<6L). + Picornaviridae Enterovirus coxsackievirus A16 (CVA16)" + cores: [Structural Biology Core] + +- name: Expression and purification of truncated Zika virus NS5 RNA-Dependent RNA Polymerase for structural studies + url: https://www.protocols.io/view/expression-and-purification-of-truncated-zika-viru-dsre6d3e/v1 + category: Protein Production + target: ZIKV + author: Anu V Chandran + date: 2025-04-25 + version: v1 + description: "We present a detailed protocol for the expression and purification of a truncated form of Zika virus (ZIKV) NS5 RNA-dependent RNA polymerase (RdRp), comprising residues 306-903. The construct contains an N-terminal hexahistidine-SUMO tag and was expressed in E. coli Lemo21 cells. The protein was ..." + cores: [Structural Biology Core] + +- name: "Large scale EV-A71 2A protease mature and precursor expression setup and operation of Single Use Bubble Column Reactors: Litre-Scale Expression of Recombinant Proteins for Structural Biology and Drug Design (SBDD)" + url: https://www.protocols.io/view/large-scale-ev-a71-2a-protease-mature-and-precurso-g3ptbymnp/v1 + category: Protein Production + target: EV-A71 2A protease + author: Nathan Wright + date: 2025-07-04 + version: v1 + description: "This protocol describes a single-use Bubble Column Reactor (suBCR) system for large-scale recombinant protein production in E. coli, addressing limitations of traditional shake-flask methods for structure-based drug discovery. The system enables parallel 1-liter batch cultivation using disposable..." + cores: [Structural Biology Core] + +- name: "Large scale MPro MERS-CoV protein expression setup and operation of Single Use Bubble Column Reactors : Litre-Scale Expression of Recombinant Proteins for Structural Biology and Drug Design (SBDD)" + url: https://www.protocols.io/view/large-scale-mpro-mers-cov-protein-expression-setup-g256byg9f/v1 + category: Protein Production + target: MERS-CoV Mpro + author: Nathan Wright + date: 2025-06-20 + version: v1 + description: "This protocol describes a novel single-use Bubble Column Reactor (suBCR) array system for large-scale recombinant protein production in E. coli, specifically demonstrated with MERS-CoV main protease (MPro). Traditional shake-flask methods are inadequate for meeting the high protein quantities req..." + cores: [Structural Biology Core] + +- name: MERS-CoV Mpro large scale purification protocol + url: https://www.protocols.io/view/mers-cov-mpro-large-scale-purification-protocol-dzbs72ne/v2 + category: Protein Production + target: MERS-CoV Mpro + author: Korvus Wang + date: 2025-06-20 + version: v2 + description: "This protocol details the expression and purification of MERS-CoV Mpro construct bearing a N-terminal His-SUMO tag at large scale (>6L)." + cores: [Structural Biology Core] + +- name: "Master_Setup and Operation of Single Use (SUB) Bubble Column Reactors (BCR): Litre-Scale Expression of Recombinant Proteins for Structural Biology and Drug Design (SBDD)." + url: https://www.protocols.io/view/master-setup-and-operation-of-single-use-sub-bubbl-dcp72vrn/v1 + category: Protein Production + target: General + author: Nathan Wright + date: 2025-05-27 + version: v1 + description: "Structure-Based Drug Discovery (SBDD) is an approach to drug design which involves crystallising disease target proteins unbound and with candidate small-molecule binders, to observe and analyse the binding interaction, or to identify novel binders that can be developed into lead-like compounds. ..." + cores: [Structural Biology Core] + +- name: "Parallel rapid expression and purification of proteins for crystallography (PREPX): 48x 100 mL cultures" + url: https://www.protocols.io/view/parallel-rapid-expression-and-purification-of-prot-c8wbzxan/v2 + category: Protein Production + target: General + author: Michael Fairhead + date: 2024-02-08 + version: v2 + description: "This protocol details the parallel rapid expression and purification of 24x proteins for crystallography (PREPX) at 100 mL culture scale. Recombinant proteins are expressed in Escherichia coli using the autoinduction method and then purified in parallel using a IMAC, desalt, tag cleavage, reverse..." + cores: [Structural Biology Core] + +- name: "Parallel rapid expression and purification of proteins for crystallography (PREPX): large scale 1 L cultures" + url: https://www.protocols.io/view/parallel-rapid-expression-and-purification-of-prot-c8exztfn/v1 + category: Protein Production + target: General + author: Michael Fairhead + date: 2024-01-30 + version: v1 + description: "This protocol details the parallel rapid expression and purification of proteins for crystallography (PREPX) at a 1 L culture scale. Recombinant proteins are expressed in Escherichia coli using the autoinduction method and then purified in parallel using a IMAC, desalt, tag cleavage, reverse IMAC..." + cores: [Structural Biology Core] + +- name: SARS-CoV-2 Mpro small scale expression and purification protocol + url: https://www.protocols.io/view/sars-cov-2-mpro-small-scale-expression-and-purifi-g3pvbymn7/v2 + category: Protein Production + target: SARS-CoV-2 Mpro + author: Korvus Wang + date: 2025-06-20 + version: v2 + description: "This protocol details the expression and purification of SARS-CoV-2 Mpro construct bearing a N-terminal His-SUMO tag at small scale (<6L). In this new version, we added the Addgene id." + cores: [Structural Biology Core] + +- name: SARS-CoV-2 nsp3 macrodomain His-SUMO tagged expression and purification protocol for crystallization + url: https://www.protocols.io/view/sars-cov-2-nsp3-macrodomain-his-sumo-tagged-expres-g2q4bydyx/v2 + category: Protein Production + target: SARS-CoV-2 nsp3 macrodomain + author: Korvus Wang + date: 2025-06-05 + version: v2 + description: "This protocol details the expression and purification of SARS-CoV-2 nsp3 macrodomain crystallization construct bearing a N-terminal His-SUMO tag and truncation of the N-terminal methionine at small scale (<6L). In this version we added the Addgene id." + cores: [Structural Biology Core] + +- name: SARS-CoV-2 nsp3 macrodomain His-tagged expression and purification protocol for assay + url: https://www.protocols.io/view/sars-cov-2-nsp3-macrodomain-his-tagged-expression-g3gebyjtf/v3 + category: Protein Production + target: SARS-CoV-2 nsp3 macrodomain + author: Korvus Wang + date: 2025-06-17 + version: v3 + description: "This protocol details the expression and purification of SARS-CoV-2 nsp3 macrodomain assay construct bearing a N-terminal His tag at small scale (<6L). In this new version, we added the addgene ID of the plasmid used." + cores: [Structural Biology Core] + +- name: SARS-CoV-2 nsp3 macrodomain expression and purification protocol for crystallization + url: https://www.protocols.io/view/sars-cov-2-nsp3-macrodomain-expression-and-purific-g2q2bydyf/v2 + category: Protein Production + target: SARS-CoV-2 nsp3 macrodomain + author: Korvus Wang + date: 2025-06-05 + version: v2 + description: "This protocol details the expression and purification of SARS-CoV-2 nsp3 macrodomain crystallization construct bearing a N-terminal His-tag at small scale (<6L). In this new version we added the Addgene id." + cores: [Structural Biology Core] + +- name: "Setup and Operation of Single Use (SUB) Bubble Column Reactors (BCR) for Recombinant Proteins: Litre-Scale Expression of SARS-CoV-2 Nucleocapsid C-terminal oligomerization domain for Structural Biology and Drug Design (SBDD)" + url: https://www.protocols.io/view/setup-and-operation-of-single-use-sub-bubble-colum-g6yebzftf/v1 + category: Protein Production + target: SARS-CoV-2 N protein + author: Nathan Wright + date: 2025-08-04 + version: v1 + description: "This study presents a scalable method for recombinant expression of SARS-CoV-2 nucleocapsid protein C-terminal oligomerization domain using single-use bubble column reactors (suBCRs) for structural biology and drug discovery applications. The nucleocapsid protein is essential for viral assembly, ..." + cores: [Structural Biology Core] + +- name: "Setup and Operation of Single Use (SUB) Bubble Column Reactors (BCR) for Recombinant Proteins: Litre-Scale Expression of enterovirus 3C protease for Structural Biology and Drug Design (SBDD)" + url: https://www.protocols.io/view/setup-and-operation-of-single-use-sub-bubble-colum-g6aabzaaf/v1 + category: Protein Production + target: Enterovirus 3C + author: Nathan Wright + date: 2025-07-29 + version: v1 + description: "Recombinant expression of enterovirus 3C proteases from EV-D68 and EV-A71 strains requires scalable cultivation methods to produce sufficient protein quantities for structural biology applications. This protocol describes the setup and operation of single-use Bubble Column Reactors (suBCR) for pa..." + cores: [Structural Biology Core] + +- name: Small-scale Expression and Purification Protocol for His-SUMO Tagged Enterovirus D68 Strain STL 2014 12 3C Protease in E. coli + url: https://www.protocols.io/view/small-scale-expression-and-purification-protocol-f-dfk73kzn/v1 + category: Protein Production + target: EV-D68 3C protease + author: Korvus Wang + date: 2025-04-25 + version: v1 + description: "This protocol describes the expression and purification of Enterovirus D68 (EV-D68) strain EV-D68 STL 2014 12 3C protease in E. coli Rosetta BL21(DE3)-RR cells. The protein is expressed with an N-terminal His-SUMO tag using an auto-induction system at 18°C. Purification involves cell lysis, initi..." + cores: [Structural Biology Core] + +- name: "The Manufacture and Setup of Single Use (SUB) Bubble Column Reactors (BCR): Litre-Scale Expression of Recombinant Proteins for Structural Biology and Drug Design (SBDD)." + url: https://www.protocols.io/view/the-manufacture-and-setup-of-single-use-sub-bubble-dzsi76ce/v1 + category: Protein Production + target: General + author: Nathan Wright + date: 2025-05-27 + version: v1 + description: "Structure-Based Drug Discovery (SBDD) is an approach to drug design which involves crystallising disease target proteins unbound and with candidate small-molecule binders, to observe and analyse the binding interaction, or to identify novel binders that can be developed into lead-like compounds. ..." + cores: [Structural Biology Core] + +- name: "West Nile Virus NS2B-NS3 inactive fusion protease expression and purification: large scale 1 L cultures" + url: https://www.protocols.io/view/west-nile-virus-ns2b-ns3-inactive-fusion-protease-g2qbbydsp/v2 + category: Protein Production + target: WNV NS2B-NS3 + author: Michael Fairhead + date: 2025-06-05 + version: v2 + description: "This method describes a protocol for the 1 L scale expression and purification of West Nile Virus NS2B-NS3 inactive fusion protease in E. coli using autoinduction growth media. After enzyme detergent based cell lysis the fusion protein is purified using his tag chromatography, TEV protease tag cl..." + cores: [Structural Biology Core] + +- name: West Nile virus NS2B-NS3 protease fusion construct small scale expression and purification protocol + url: https://www.protocols.io/view/west-nile-virus-ns2b-ns3-protease-fusion-construct-g2ngbydbx/v3 + category: Protein Production + target: WNV NS2B-NS3 + author: Korvus Wang + date: 2025-06-04 + version: v3 + description: "This protocol details the co-expression and purification of West Nile virus NS2B-NS3 protease fusion construct bearing a N-terminal His-StrepII tag at small scale (<6L). This protocol produces enzymatically active product that is suitable for biochemical assays. In this version we added the Addge..." + cores: [Structural Biology Core] + +- name: Zika NS2B-3-4A Protein Construct cleavage pattern assay + url: https://www.protocols.io/view/zika-ns2b-3-4a-protein-construct-cleavage-pattern-d5fq83mw/v1 + category: Protein Production + target: ZIKV + author: Adeeba Dhalech + date: 2025-08-13 + version: v1 + description: "Cis cleavage pattern by viral protease is analyzed using an expression plasmid pT7CFE1-NHA-Chis-target of interest. For flaviviruses (ZIka/DENV) the plasmid has been designed to include the cofactor domain of NS2B, NS2B-3 cleavage site, protease and helicase domains of NS3, and first 49 residues ..." + cores: [Structural Biology Core] + +- name: Zika NS2B-NS3 fusion construct for assay small scale expression and purification protocol + url: https://www.protocols.io/view/zika-ns2b-ns3-fusion-construct-for-assay-small-sca-g2m8byc9x/v2 + category: Protein Production + target: ZIKV NS2B-NS3 + author: Korvus Wang + date: 2025-06-04 + version: v2 + description: "This protocol details the co-expression and purification of Zika virus NS2B-NS3 protease fusion construct bearing a N-terminal His-StrepII tag at small scale (<6L). The purified enzyme is active and suitable for use in biochemical assays. Construct used here is (internal id: QQ01ZVNS2B-cC001). In..." + cores: [Structural Biology Core] + +- name: Zika NS2B-NS3 protease co-expression construct small scale expression and purification protocol + url: https://www.protocols.io/view/zika-ns2b-ns3-protease-co-expression-construct-sma-g3pybympx/v2 + category: Protein Production + target: ZIKV NS2B-NS3 + author: Korvus Wang + date: 2025-06-20 + version: v2 + description: "This protocol details the co-expression and purification of Zika NS2B-NS3 protease coexpression construct bearing a N-terminal His-GST tag at small scale (<6L). In this new version, we added the Addgene id." + cores: [Structural Biology Core] + +- name: Zika NS5 RdRp His-SUMO construct small scale expression and purification protocol + url: https://www.protocols.io/view/zika-ns5-rdrp-his-sumo-construct-small-scale-expre-dfh93j96/v1 + category: Protein Production + target: ZIKV NS5 RdRp + author: Korvus Wang + date: 2024-08-08 + version: v1 + description: "This protocol details the co-expression and purification of Zika NS5 NS5 RNA-dependent RNA polymerase bearing a N-terminal His-SUMO tag at small scale (<6L)." + cores: [Structural Biology Core] + +- name: Zika NS5 RdRp Histidine-Thioredoxin tagged construct small scale expression and purification protocol + url: https://www.protocols.io/view/zika-ns5-rdrp-histidine-thioredoxin-tagged-constru-dfkw3kxe/v1 + category: Protein Production + target: ZIKV NS5 RdRp + author: Korvus Wang + date: 2025-04-22 + version: v1 + description: "We present a comprehensive small-scale (<6L) protocol for the expression and purification of the Zika virus NS5 RNA-dependent RNA polymerase (RdRp) domain with an N-terminal His-Trx (Histidine-Thioredoxin) tag. Using the BL21(DE3)-RR E. coli expression system, the protocol describes bacterial tra..." + cores: [Structural Biology Core] + +- name: "Zika Virus NS2B-NS3 protease fusion protein his10-tagged protein expression and purification: large scale 1 L cultures" + url: https://www.protocols.io/view/zika-virus-ns2b-ns3-protease-fusion-protein-his10-dp4b5qsn/v1 + category: Protein Production + target: ZIKV NS2B-NS3 + author: Michael Fairhead + date: 2024-10-23 + version: v1 + description: "This protocol details the expression and purification of Zika Virus NS2B-NS3 protease fusion protein with a his10-tag for biophysical assay at a 1 L culture scale. Recombinant proteins are expressed in Escherichia coli using the autoinduction method and then purified in using a IMAC, desalt, tag ..." + cores: [Structural Biology Core] + +# Biophysical Assay Protocols +- name: "Creoptix Protein Immobilization Protocol: Biotin Capture on Streptavidin Chip" + url: https://www.protocols.io/view/creoptix-protein-immobilization-protocol-biotin-ca-dyy47xyw/v1 + category: Biophysical Assay + target: General + author: Eda Capkin + date: 2025-04-15 + version: v1 + description: "This protocol provides a quick yet comprehensive method for the capture of various biotinylated +proteins on a PCH-STA chip, that preserves protein activity. The procedure covers system preparation, chip conditioning, protein capture, and subsequent analysis using the Creoptix WAVEsystem. It is a ..." + cores: [Structural Biology Core] + +- name: "Creoptix Protein Immobilization Protocol: His-tag Capture via EDC/NHS chemistry" + url: https://www.protocols.io/view/creoptix-protein-immobilization-protocol-his-tag-c-dibf4ajn/v1 + category: Biophysical Assay + target: General + author: Eda Capkin + date: 2025-02-21 + version: v1 + description: "This protocol outlines a comprehensive method for immobilizing His-tagged proteins on a PCH-NTA chip using the Creoptix WAVEsystem. The procedure involves chip conditioning, protein capture, and covalent immobilization through His capture and EDC/NHS chemistry. Key steps include surface activatio..." + cores: [Structural Biology Core] + +- name: Data Analysis waveRAPID using Creoptix WAVEsystem + url: https://www.protocols.io/view/data-analysis-waverapid-using-creoptix-wavesystem-dp685rhw/v1 + category: Biophysical Assay + target: General + author: Eda Capkin + date: 2025-02-21 + version: v1 + description: "This protocol outlines the data analysis workflow for the Creoptix WAVEsystem using Repeated Analyte Pulses of Increasing Duration (RAPID) method. It covers essential steps including blank and DMSO corrections, and kinetic analysis using a 1:1 binding model. The procedure ensures accurate evaluat..." + cores: [Structural Biology Core] + +- name: Dengue 2 NS2B-NS3 protease binding assay for compound screen using grating-coupled interferometry + url: https://www.protocols.io/view/dengue-2-ns2b-ns3-protease-binding-assay-for-compo-dyy37xyn/v1 + category: Biophysical Assay + target: DENV NS2B-NS3 + author: Eda Capkin + date: 2025-04-15 + version: v1 + description: "This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Dengue virus NS2B-NS3 protease using the Creoptix Wave system. Grating coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, ..." + cores: [Structural Biology Core] + +- name: Isothermal titration calorimetry protocol for binding studies of enterovirus EV-A71 2A protease and small inhibitors + url: https://www.protocols.io/view/isothermal-titration-calorimetry-protocol-for-bind-gzx7bx7rp/v1 + category: Biophysical Assay + target: EV-A71 2A protease + author: Eda Capkin + date: 2025-07-29 + version: v1 + description: "This protocol describes an isothermal titration calorimetry (ITC) method for measuring binding interactions between the 2A protease from enterovirus stratin EV-71 and small molecule inhibitors. Experiments are performed at 25°C using 25 μM protein and 250 μM ligand concentrations with 17 sequen..." + cores: [Structural Biology Core] + +- name: Kinetic assay with waveRAPID grating-coupled interferometry waveCreoptix system + url: https://www.protocols.io/view/kinetic-assay-with-waverapid-grating-coupled-inte-dp655rg6/v1 + category: Biophysical Assay + target: General + author: Eda Capkin + date: 2025-02-24 + version: v1 + description: "This protocol outlines the setup of kinetic binding assays using the Creoptix waveRAPID grating-coupled interferometry system. The method covers automated sample handling in 96- or 384-well formats, including DMSO corrections, control samples, and buffer blanks, enabling high-throughput molecular..." + cores: [Structural Biology Core] + +- name: Zika virus NS2B-NS3 protease binding assay for compound screen using grating-coupled interferometry + url: https://www.protocols.io/view/zika-virus-ns2b-ns3-protease-binding-assay-for-com-dpxj5pkn/v1 + category: Biophysical Assay + target: ZIKV NS2B-NS3 + author: Eda Capkin + date: 2025-02-24 + version: v1 + description: "This protocol aims to measure kinetic parameters (ka, kd, and KD) for compounds against Zika virus NS2B-NS3 protease using the Creoptix Wave system. Grating coupled interferometry (GCI) is a label-free technique to measure kinetics and affinity for different targets (proteins, small molecules, fr..." + cores: [Structural Biology Core] + +# ADMET Protocols +- name: Assessing Intestinal and CNS Permeability with MDR1-MDCKII Cells + url: https://www.protocols.io/view/assessing-intestinal-and-cns-permeability-with-mdr-djuf4ntn/v1 + category: ADMET + target: General + author: Anzhela Rodnichenko + date: 2024-12-09 + version: v1 + description: "The protocol allows measurement of the rate of flux of a compound to identify intestinal or CNS permeability. The assay measures the rate of flux across Canine MDR1 Knockout, Human MDR1 Knockin MDCKII cells (MDR1-MDCKII) cell monolayers to identify intestinal or CNS permeability. By measuring ho..." + cores: [ADMET Core] + +- name: Drug transporter (ABC), P-gp, BCRP, BSEP inhibition using drug substrate assay + url: https://www.protocols.io/view/drug-transporter-abc-p-gp-bcrp-bsep-inhibition-usi-gz6rbx9d7/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "ATP-binding cassette (ABC) transporter assays are used to study the activity and interaction of drugs with ABC transporters P-gp, BCRP, and BSEP, which are crucial for drug absorption, distribution, and excretion.  These assays measure the effect of a test compound on the transport of a known pro..." + cores: [ADMET Core] + +- name: Drug transporter (SLC) inhibition panel assay using drug substrates + url: https://www.protocols.io/view/drug-transporter-slc-inhibition-panel-assay-using-g2k5bycy7/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "SLC (Solute Carrier) transporters play a crucial role in drug absorption, distribution, and elimination. Some drugs can act as inhibitors of these transporters, potentially affecting the absorption or clearance of other co-administered drugs, leading to drug interactions. This can result in alter..." + cores: [ADMET Core] + +- name: Fetal Calf Serum (FCS / FBS) Protein Binding + url: https://www.protocols.io/view/fetal-calf-serum-fcs-fbs-protein-binding-dvyn67ve/v1 + category: ADMET + target: General + author: Yurii Kheilik + date: 2025-03-31 + version: v1 + description: "In vitro pharmacological and toxicological evaluation of chemicals is performed using a wide variety of cell‐based assay systems. One of the major factors influencing the in vitro responses of chemicals is the amount of unbound chemicals present at the target site. The concentrations of the unbou..." + cores: [ADMET Core] + +- name: In-Vivo Mouse and Rat PK Bioanalysis + url: https://www.protocols.io/view/in-vivo-mouse-and-rat-pk-bioanalysis-gz75bx9q7/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "In vivo PK bioanalysis involves studying drug behaviour within a living organism to understand how it is absorbed, distributed, metabolized, and excreted (ADME). This is crucial for drug discovery and development, providing insights into a drug's efficacy and safety before clinical trials. Bioana..." + cores: [ADMET Core] + +- name: In-vitro plasma protein binding + url: https://www.protocols.io/view/in-vitro-plasma-protein-binding-gzzzbx777/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "In vitro plasma protein binding studies in various animal models (Human, rat, mouse, dog, fetal calf serum) are crucial for understanding drug behaviour and predicting human responses. These studies help determine how a drug interacts with plasma proteins, influencing its distribution, metabolism..." + cores: [ADMET Core] + +- name: In-vitro CYP inhibition pooled + url: https://www.protocols.io/view/in-vitro-cyp-inhibition-pooled-gzz5bx787/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "This assay is crucial for understanding a compound's inhibitory profile across major drug-metabolizing enzymes, providing essential data for predicting clinical drug-drug interactions and supporting regulatory submissions in pharmaceutical development. An in vitro CYP inhibition assay evaluates t..." + cores: [ADMET Core] + +- name: In-vitro Human or Mouse S9 intestinal stability assay + url: https://www.protocols.io/view/in-vitro-human-or-mouse-s9-intestinal-stability-as-gzz3bx78p/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "A stability intestinal S9 human or mouse assay, or intestinal S9 stability assay, is an in vitro test used to assess the metabolic stability of a compound in the presence of human or mouse intestinal enzymes. It simulates the breakdown of a compound by enzymes found in the small intestine, provid..." + cores: [ADMET Core] + +- name: In-vitro MDR1-MDCKII permeability assay + url: https://www.protocols.io/view/in-vitro-mdr1-mdckii-permeability-assay-gz4gbx8tx/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "In vitro MDR1-MDCKII permeability assays are used to assess the ability of drug candidates to cross the blood-brain barrier (BBB) and to identify P-glycoprotein (P-gp) substrates and inhibitors. MDR1-MDCKII cells, which express the human P-gp protein, are grown on semi-permeable supports and used..." + cores: [ADMET Core] + +- name: In-vitro Mouse or Human Blood stability assay + url: https://www.protocols.io/view/in-vitro-mouse-or-human-blood-stability-assay-gzz2bx78f/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "In vitro blood stability is a key aspect of DMPK (Drug Metabolism and Pharmacokinetics) research, focusing on how a drug candidate behaves within the blood in a controlled laboratory environment. This involves evaluating the compound's stability, its rate of degradation, and its potential for int..." + cores: [ADMET Core] + +- name: In-vitro Thermodynamic Solubility + url: https://www.protocols.io/view/in-vitro-thermodynamic-solubility-gzz4bx78x/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "A thermodynamic solubility assay measures the maximum amount of a compound that can dissolve in a given solvent under specific conditions at equilibrium. It's a crucial assay for understanding a compound's true solubility, particularly in formulations and early drug development. This method helps..." + cores: [ADMET Core] + +- name: In-vitro hERG & NaV1.5 cardiotoxicity assay + url: https://www.protocols.io/view/in-vitro-herg-amp-nav1-5-cardiotoxicity-assay-gz4jbx8up/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "In vitro hERG and NaV1.5 cardiotoxicity assays are crucial for evaluating the potential of new drugs to cause cardiac arrhythmias. These assays involve measuring the effects of compounds on the hERG (human ether-à-go-go-related gene) and NaV1.5 (sodium channel) ion channels, which play vital role..." + cores: [ADMET Core] + +- name: LogP / LogD shake-flask method + url: https://www.protocols.io/view/logp-logd-shake-flask-method-djue4nte/v1 + category: ADMET + target: General + author: Yurii Kheylik + date: 2024-09-23 + version: v1 + description: "Lipophilicity is possibly the most important physicochemical parameter for any potential drug candidate. Lipophilicity measurements are valuable for understanding how drugs are dissolved in plasma and other aqueous biological fluids. Lipophilicity is typically accessed as the distribution of the ..." + cores: [ADMET Core] + +- name: Metabolic stability assay in human, rat, dog or mouse hepatocytes + url: https://www.protocols.io/view/metabolic-stability-assay-in-human-rat-dog-or-mous-gzztbx76p/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "Metabolic stability, measured in hepatocytes, refers to the rate at which a drug compound is metabolized or broken down by liver cells. This is a critical aspect of drug discovery and development, as it helps determine how long a drug will remain in the body and at what concentration it will exer..." + cores: [ADMET Core] + +- name: Metabolic stability assay in rat or dog microsomes + url: https://www.protocols.io/view/metabolic-stability-assay-in-rat-or-dog-microsomes-gzzvbx767/v1 + category: ADMET + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "Metabolic stability, in the context of liver microsomes, refers to how quickly a drug candidate is metabolized (broken down) by the liver's enzyme system, specifically within the microsomes. This is measured by incubating a drug with microsomes and determining how much of the original drug remain..." + cores: [ADMET Core] + +- name: Microsomal stability assay for human and mouse liver microsomes - drug metabolism + url: https://www.protocols.io/view/microsomal-stability-assay-for-human-and-mouse-liv-djug4ntw/v1 + category: ADMET + target: General + author: Lina Bortnichuk + date: 2024-12-09 + version: v1 + description: "Microsomal stability is a key parameter in drug discovery and development to support understanding of a compound's susceptibility to liver metabolism. This assay assesses a compound's susceptibility to metabolism by liver enzymes, primarily cytochrome P450 (CYP) enzymes. Using either human or mo..." + cores: [ADMET Core] + +- name: Plasma Protein Binding Equilibrium Dialysis for Human, Rat and Mouse Plasma + url: https://www.protocols.io/view/plasma-protein-binding-equilibrium-dialysis-for-hu-dvym67u6/v1 + category: ADMET + target: General + author: Yurii Kheilik + date: 2025-03-31 + version: v1 + description: "Fraction unbound (fu) is a critical parameter that needs to be measured accurately because it has significant impacts on the predictions of drug-drug interactions, estimations of therapeutic indices, and developments of PK/PD relationships. Moreover, Plasma Protein Binding (PPB) is critical when ..." + cores: [ADMET Core] + +- name: Shake-Flask Aqueous Solubility assay (Kinetic solubility) + url: https://www.protocols.io/view/shake-flask-aqueous-solubility-assay-kinetic-solub-djtz4np6/v1 + category: ADMET + target: General + author: Dmytro Lesyk + date: 2024-12-09 + version: v1 + description: "Determining compound solubility is an essential tool for the early stages of the drug discovery process, as well as for lead optimization. Low solubility can lead to unpredictable and unreliable results during in vitro testing, thereby increasing the development costs. Solubility issues at the la..." + cores: [ADMET Core] + +# Antiviral Assay Protocols +- name: 50% Tissue Culture Infectious Dose (TCID50) for SARS-CoV-2 + url: https://www.protocols.io/view/50-tissue-culture-infectious-dose-tcid50-for-sars-df8g3rtw/v2 + category: Antiviral Assay + target: SARS-CoV-2 + author: Briana L McGovern + date: 2025-08-04 + version: v2 + description: "To establish a reliable TCID50 screening assay for quantifying SARS-CoV-2 infectivity in cell culture systems and support downstream applications in therapeutic development. Protocol used to titer both animal tissue samples and viral stocks at BSL-3. The 50% Tissue Culture Infectious Dose (TCID50..." + cores: [Antiviral Assay Core] + +- name: A549-ACE2 SARS-CoV-1 antiviral effect screening assay + url: https://www.protocols.io/view/a549-ace2-sars-cov-1-antiviral-effect-screening-as-g6w6bzfhf/v1 + category: Antiviral Assay + target: SARS-CoV-1 + author: Nick Lynch + date: 2025-10-26 + version: v1 + description: "To evaluate the antiviral efficacy of compounds against SARS-CoV-1 infection using an engineered A549-ACE2 cell line model. A549 human lung adenocarcinoma cells stably transfected to express ACE2 receptors were used as the host cell system. Cells were pre-treated with a range of test compounds pr..." + cores: [Antiviral Assay Core] + +- name: Antiviral In Vitro Screening Using SARS-CoV-2 and MERS-CoV - Cytotoxicity of Drugs + url: https://www.protocols.io/view/antiviral-in-vitro-screening-using-sars-cov-2-and-d58u89ww/v1 + category: Antiviral Assay + target: SARS-CoV-2 + author: Nadine Alvarez + date: 2025-08-03 + version: v1 + description: "The protocol evaluates compounds to determine their antiviral activity against coronaviruses. The antiviral activity is evaluated based on the 50% inhibitory concentration (IC50) and the 50% effective concentration (EC50). Two cell lines can be used for these assays (A549+ACE2+TMP (Invivogen) or ..." + cores: [Antiviral Assay Core] + +- name: Calculating Multiplicity of Infection (MOI) + url: https://www.protocols.io/view/calculating-multiplicity-of-infection-moi-dik24cye/v1 + category: Antiviral Assay + target: General + author: Briana L McGovern + date: 2025-03-18 + version: v1 + description: "Multiplicity of infection (MOI) is the ratio of viral particles to cells. The ideal MOI for antiviral screenings will depend on several things - the cell type, the cell passage, the virus type, the amount of cells, etc." + cores: [Antiviral Assay Core] + +- name: Coronavirus protease panel anti viral assay using 293T cells + url: https://www.protocols.io/view/coronavirus-protease-panel-anti-viral-assay-using-d7rq9m5w/v1 + category: Antiviral Assay + target: Coronavirus + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "Cell-based fluorescent assay with high sensitivity and low background that reports on the activity of viral proteases, which are key drug targets. Assay is compatible with not only the SARS-CoV-2 Mpro protein but also orthologues from a range of human and nonhuman CoVs as well as clinically repor..." + cores: [Antiviral Assay Core] + +- name: Cytotoxicity Screening Assay - Paired with Antiviral Assays + url: https://www.protocols.io/view/cytotoxicity-screening-assay-paired-with-antiviral-diky4cxw/v1 + category: Antiviral Assay + target: General + author: Briana L McGovern + date: 2025-03-18 + version: v1 + description: "The following is a cytotoxicity protocol to be paired with a live virus antiviral screening in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via CC50 values generated via analysis of MTT/MTS assays in uninfected cells...." + cores: [Antiviral Assay Core] + +- name: DENGUE Antiviral Immunofluorescence staining Protocol + url: https://www.protocols.io/view/dengue-antiviral-immunofluorescence-staining-proto-d4v98w96/v1 + category: Antiviral Assay + target: DENV + author: Briana L McGovern + date: 2025-08-04 + version: v1 + description: "This protocol describes immunofluorescence staining of fixed SARS-CoV-2 infected cells using IC7C7 primary antibody (produced in house against SARS-CoV-2 NP) and Alexa Fluor 488-conjugated secondary antibody. The procedure results in fluorescently labeled infected cells for quantification of vira..." + cores: [Antiviral Assay Core] + +- name: Generating Antiviral & Cytotoxicity Curves + url: https://www.protocols.io/view/generating-antiviral-amp-cytotoxicity-curves-diqi4due/v1 + category: Antiviral Assay + target: General + author: Briana L McGovern + date: 2025-03-18 + version: v1 + description: "This describes generating Antiviral & Cytotoxicity Curves" + cores: [Antiviral Assay Core] + +- name: In Vitro Antiviral Screening assay Against Viruses of Pandemic Potential + url: https://www.protocols.io/view/in-vitro-antiviral-screening-assay-against-viruses-d5jq84mw/v1 + category: Antiviral Assay + target: General + author: Nick Lynch + date: 2025-08-03 + version: v1 + description: "This protocol details a primary cytopathic effect (CPE) reduction assay for evaluating antiviral compound efficacy. Vero 76 cell monolayers are prepared in 96-well plates and exposed to eight serial half-log10 concentrations of test compounds, along with infected and uninfected controls, and a kn..." + cores: [Antiviral Assay Core] + +- name: Influenza virus plaque assay + url: https://www.protocols.io/view/influenza-virus-plaque-assay-b5yjq7un/v1 + category: Antiviral Assay + target: Influenza + author: Steven F Baker + date: 2022-03-16 + version: v1 + description: "Determine virus concentration from cell culture, lung homogenates, and more. This protocol measures virus in plaque forming units per ml solution. This protocol differs from classic flu plaque assays by using a semi-solid overlay (Avicel) as opposed to agarose. This is beneficial in avoiding re..." + cores: [Antiviral Assay Core] + +- name: Live Virus Dengue - Vero-TMPRSS2 + PGP Inhibitor - Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-dengue-vero-tmprss2-pgp-inhibitor-antiv-dn335gqn/v1 + category: Antiviral Assay + target: DENV + author: Briana L McGovern + date: 2025-08-04 + version: v1 + description: "The following is a protocol for live virus antiviral screening against Dengue in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against Dengue. You ..." + cores: [Antiviral Assay Core] + +- name: Live Virus EV-A71 - RD - Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-ev-a71-rd-antiviral-screening-assay-d53h88j6/v1 + category: Antiviral Assay + target: EV-A71 + author: Briana L McGovern + date: 2025-08-02 + version: v1 + description: "The following is a protocol for live virus antiviral screening against EV-A71 in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against EV-A71. Eac..." + cores: [Antiviral Assay Core] + +- name: Live Virus EV-D68 - RD - Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-ev-d68-rd-antiviral-screening-assay-eb6gbarbx/v1 + category: Antiviral Assay + target: EV-D68 + author: Rebecca Pearl + date: 2025-08-02 + version: v1 + description: "The following is a protocol for live virus antiviral screening against EV-D68 in vitro using Rhabdomyosarcoma (RD) cells. RD Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluore..." + cores: [Antiviral Assay Core] + +- name: Live Virus EV-D68 - on RD cells - Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-ev-d68-on-rd-cells-antiviral-screening-hbesb2jef/v1 + category: Antiviral Assay + target: EV-D68 + author: Nick Lynch + date: 2025-10-26 + version: v1 + description: "The following is a protocol for live virus antiviral screening against EV-D68 in vitro on Rhabdomyosarcoma (RD) cells. RD Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity. IC50 values are generated via analysis of MTT/MTS data as..." + cores: [Antiviral Assay Core] + +- name: Live Virus MERS-CoV - Vero-TMPRSS2 + Pgp Inhibitor- Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-mers-cov-vero-tmprss2-pgp-inhibitor-ant-diqk4duw/v1 + category: Antiviral Assay + target: MERS-CoV + author: Briana L McGovern + date: 2025-08-03 + version: v1 + description: "The following is a protocol for live virus antiviral screening against MERS-CoV EMC2012 in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against MER..." + cores: [Antiviral Assay Core] + +- name: Live Virus SARS-CoV-2 - HeLa-ACE2 - Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-sars-cov-2-hela-ace2-antiviral-screenin-de5k3g4w/v1 + category: Antiviral Assay + target: SARS-CoV-2 + author: Briana L McGovern + date: 2025-03-18 + version: v1 + description: "The following is a protocol for live virus antiviral screening against SARS-CoV-2 in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against SARS-CoV-..." + cores: [Antiviral Assay Core] + +- name: Live Virus SARS-CoV-2 - iPSC Pneumocyte - Antiviral Screening + url: https://www.protocols.io/view/live-virus-sars-cov-2-ipsc-pneumocyte-antiviral-sc-diai4ace/v1 + category: Antiviral Assay + target: SARS-CoV-2 + author: Briana L McGovern + date: 2025-08-03 + version: v1 + description: "The following is a protocol for live virus antiviral screening against SARS-CoV-2 in iPSC pneumocyte cells. iPSC pneumocytes are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent ..." + cores: [Antiviral Assay Core] + +- name: Live Virus Zika - Vero-TMPRSS2 + PGP Inhibitor - Antiviral Screening Assay + url: https://www.protocols.io/view/live-virus-zika-vero-tmprss2-pgp-inhibitor-antivir-dm3s48ne/v1 + category: Antiviral Assay + target: ZIKV + author: Briana L McGovern + date: 2025-08-04 + version: v1 + description: "The following is a protocol for live virus antiviral screening against Zika in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against Zika. You may ..." + cores: [Antiviral Assay Core] + +- name: MERS-CoV Antiviral Immunofluorescence staining Protocol + url: https://www.protocols.io/view/mers-cov-antiviral-immunofluorescence-staining-pro-dn3s5gne/v1 + category: Antiviral Assay + target: MERS-CoV + author: Briana L McGovern + date: 2025-08-03 + version: v1 + description: "This protocol describes immunofluorescence staining of fixed SARS-CoV-2 infected cells using IC7C7 primary antibody (produced in house against SARS-CoV-2 NP) and Alexa Fluor 488-conjugated secondary antibody. The procedure results in fluorescently labeled infected cells for quantification of vira..." + cores: [Antiviral Assay Core] + +- name: SARS-CoV-2 Antiviral Immunofluorescence staining Protocol + url: https://www.protocols.io/view/sars-cov-2-antiviral-immunofluorescence-staining-p-diqa4dse/v1 + category: Antiviral Assay + target: SARS-CoV-2 + author: Briana L McGovern + date: 2025-03-18 + version: v1 + description: "This protocol describes immunofluorescence staining of fixed SARS-CoV-2 infected cells using IC7C7 primary antibody (produced in house against SARS-CoV-2 NP) and Alexa Fluor 488-conjugated secondary antibody. The procedure results in fluorescently labeled infected cells for quantification of vira..." + cores: [Antiviral Assay Core] + +- name: Using the Tecan D300e + url: https://www.protocols.io/view/using-the-tecan-d300e-dfgw3jxe/v1 + category: Antiviral Assay + target: General + author: Briana L McGovern + date: 2025-03-18 + version: v1 + description: "Using Tecan D300e for serial dilution" + cores: [Antiviral Assay Core] + +- name: ZIKA Antiviral Immunofluorescence staining Protocol + url: https://www.protocols.io/view/zika-antiviral-immunofluorescence-staining-protoco-dm3x48pn/v1 + category: Antiviral Assay + target: ZIKV + author: Briana L McGovern + date: 2025-08-04 + version: v1 + description: "This protocol describes immunofluorescence staining of fixed SARS-CoV-2 infected cells using IC7C7 primary antibody (produced in house against SARS-CoV-2 NP) and Alexa Fluor 488-conjugated secondary antibody. The procedure results in fluorescently labeled infected cells for quantification of vira..." + cores: [Antiviral Assay Core] + +- name: iPSC Pneumocyte Live Virus SARS-CoV-2 Cytotoxicity Screening Assay + url: https://www.protocols.io/view/ipsc-pneumocyte-live-virus-sars-cov-2-cytotoxicity-dip94dr6/v1 + category: Antiviral Assay + target: SARS-CoV-2 + author: Briana L McGovern + date: 2025-08-03 + version: v1 + description: "These immunofluorescence-based antiviral assays rely on identification of infected cells through immunostaining the NP (influenza virus), N (SARS-CoV-2) proteins, or any relevant viral antigen at 488nM and counterstaining with DAPI. Infected cells (488nM) and total cells (DAPI) are identified and..." + cores: [Antiviral Assay Core] + diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_40a4cdd72ec5afc0.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_40a4cdd72ec5afc0.png new file mode 100644 index 000000000..65e50461e Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_40a4cdd72ec5afc0.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_4d04baa975633d87.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_4d04baa975633d87.png new file mode 100644 index 000000000..f3c5eba64 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_4d04baa975633d87.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_5e5c2c6bd5e90fa5.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_5e5c2c6bd5e90fa5.png new file mode 100644 index 000000000..df84f1347 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_5e5c2c6bd5e90fa5.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_6bee95e244c80b68.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_6bee95e244c80b68.png new file mode 100644 index 000000000..d89b88212 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_6bee95e244c80b68.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_80885d3d6523dc10.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_80885d3d6523dc10.png new file mode 100644 index 000000000..06e0e23fb Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_80885d3d6523dc10.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_a919526333abd077.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_a919526333abd077.png new file mode 100644 index 000000000..e8a5bdf16 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_a919526333abd077.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_bcc3ba6b8ca7cb28.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_bcc3ba6b8ca7cb28.png new file mode 100644 index 000000000..f4aa155ac Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_bcc3ba6b8ca7cb28.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_bd54ab072a7dfe3e.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_bd54ab072a7dfe3e.png new file mode 100644 index 000000000..03e9af160 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_bd54ab072a7dfe3e.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_bf6440df3b94b2b7.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_bf6440df3b94b2b7.png new file mode 100644 index 000000000..2383843ee Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_bf6440df3b94b2b7.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-completed_hu_d92c16a1aba211af.png b/resources/_gen/images/images/icons/tep-stage-completed_hu_d92c16a1aba211af.png new file mode 100644 index 000000000..9f92a7ff3 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-completed_hu_d92c16a1aba211af.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_18f95058c07a9cba.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_18f95058c07a9cba.png new file mode 100644 index 000000000..7aacd9c99 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_18f95058c07a9cba.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_1d03a2f5382d3346.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_1d03a2f5382d3346.png new file mode 100644 index 000000000..e56a13435 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_1d03a2f5382d3346.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_4a0f296a4a9c41e7.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_4a0f296a4a9c41e7.png new file mode 100644 index 000000000..7ddf2c147 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_4a0f296a4a9c41e7.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_61450b1ce367a327.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_61450b1ce367a327.png new file mode 100644 index 000000000..a370b5a6b Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_61450b1ce367a327.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_9c2d48e54073a190.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_9c2d48e54073a190.png new file mode 100644 index 000000000..76f3468df Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_9c2d48e54073a190.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_b25bfff362388ee4.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_b25bfff362388ee4.png new file mode 100644 index 000000000..61f46a9f3 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_b25bfff362388ee4.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-in-progress_hu_d3d08bae746d968b.png b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_d3d08bae746d968b.png new file mode 100644 index 000000000..c1eabe1cd Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-in-progress_hu_d3d08bae746d968b.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_23831ca1b3323b04.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_23831ca1b3323b04.png new file mode 100644 index 000000000..ee0eb5432 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_23831ca1b3323b04.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_870f55265e16bc2d.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_870f55265e16bc2d.png new file mode 100644 index 000000000..64b92e7bc Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_870f55265e16bc2d.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_878c77b33ff4bf7d.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_878c77b33ff4bf7d.png new file mode 100644 index 000000000..6e4a54be7 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_878c77b33ff4bf7d.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_92b7294d682f3f20.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_92b7294d682f3f20.png new file mode 100644 index 000000000..86999ebb2 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_92b7294d682f3f20.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_9ecc6ec26ac4f691.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_9ecc6ec26ac4f691.png new file mode 100644 index 000000000..d3d521284 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_9ecc6ec26ac4f691.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_a9b0e21be169034a.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_a9b0e21be169034a.png new file mode 100644 index 000000000..46a53269d Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_a9b0e21be169034a.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_c22c5b82e2f93758.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_c22c5b82e2f93758.png new file mode 100644 index 000000000..2444f1b9e Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_c22c5b82e2f93758.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_d5406e21182c75a8.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_d5406e21182c75a8.png new file mode 100644 index 000000000..710d8b5e2 Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_d5406e21182c75a8.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_e1dfaa103cf35df4.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_e1dfaa103cf35df4.png new file mode 100644 index 000000000..c3e9e617d Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_e1dfaa103cf35df4.png differ diff --git a/resources/_gen/images/images/icons/tep-stage-not-started_hu_f6699fc238f75337.png b/resources/_gen/images/images/icons/tep-stage-not-started_hu_f6699fc238f75337.png new file mode 100644 index 000000000..c10bee33a Binary files /dev/null and b/resources/_gen/images/images/icons/tep-stage-not-started_hu_f6699fc238f75337.png differ diff --git a/themes/kube/layouts/section/docs.html b/themes/kube/layouts/section/docs.html index 4a666f13e..32249ac08 100644 --- a/themes/kube/layouts/section/docs.html +++ b/themes/kube/layouts/section/docs.html @@ -9,7 +9,7 @@

{{ .Title }}

{{ range .Pages.ByWeight }}
-

{{ .Title }}

+

{{ .Title }}

{{ .Params.description }}

{{ end }} diff --git a/themes/kube/layouts/shortcodes/antiviral-protocols.html b/themes/kube/layouts/shortcodes/antiviral-protocols.html new file mode 100644 index 000000000..e3afbb7b4 --- /dev/null +++ b/themes/kube/layouts/shortcodes/antiviral-protocols.html @@ -0,0 +1,5 @@ +{{ range $.Site.Data.outputs.antiviral_protocols }} + + {{ partial "research-output.html" . }} + +{{ end }} diff --git a/themes/kube/layouts/shortcodes/biophysical-protocols.html b/themes/kube/layouts/shortcodes/biophysical-protocols.html new file mode 100644 index 000000000..c9043f6ad --- /dev/null +++ b/themes/kube/layouts/shortcodes/biophysical-protocols.html @@ -0,0 +1,5 @@ +{{ range $.Site.Data.outputs.biophysical_protocols }} + + {{ partial "research-output.html" . }} + +{{ end }} diff --git a/themes/kube/layouts/shortcodes/chembl-datasets-table.html b/themes/kube/layouts/shortcodes/chembl-datasets-table.html new file mode 100644 index 000000000..82c666bc0 --- /dev/null +++ b/themes/kube/layouts/shortcodes/chembl-datasets-table.html @@ -0,0 +1,354 @@ + + + +
+
+ + +
+
+ + +
+
+ + +
+
+ +
+ Showing {{ len $.Site.Data.outputs.chembl_datasets }} of {{ len $.Site.Data.outputs.chembl_datasets }} datasets +
+ + + + + + + + + + + + + + {{ range $.Site.Data.outputs.chembl_datasets }} + + + + + + + + + {{ end }} + +
DatasetCategoryTargetChEMBL IDReleaseDate
+ {{ .title }} + {{ with .description }} + i{{ . }} + {{ end }} + + {{ $categoryClass := "chembl-category-biochemical" }} + {{ if eq .category "Antiviral" }}{{ $categoryClass = "chembl-category-antiviral" }}{{ end }} + {{ if eq .category "ADMET" }}{{ $categoryClass = "chembl-category-admet" }}{{ end }} + {{ if eq .category "Biophysical" }}{{ $categoryClass = "chembl-category-biophysical" }}{{ end }} + {{ .category }} + {{ .target }} + + {{ .chembl_id }} + + {{ .chembl_release }}{{ .date }}
+ + diff --git a/themes/kube/layouts/shortcodes/crystallization-protocols.html b/themes/kube/layouts/shortcodes/crystallization-protocols.html new file mode 100644 index 000000000..8c98005e2 --- /dev/null +++ b/themes/kube/layouts/shortcodes/crystallization-protocols.html @@ -0,0 +1,5 @@ +{{ range $.Site.Data.outputs.crystallization_protocols }} + + {{ partial "research-output.html" . }} + +{{ end }} diff --git a/themes/kube/layouts/shortcodes/expression-protocols.html b/themes/kube/layouts/shortcodes/expression-protocols.html new file mode 100644 index 000000000..6af46f19e --- /dev/null +++ b/themes/kube/layouts/shortcodes/expression-protocols.html @@ -0,0 +1,5 @@ +{{ range $.Site.Data.outputs.expression_protocols }} + + {{ partial "research-output.html" . }} + +{{ end }} diff --git a/themes/kube/layouts/shortcodes/protocols-table.html b/themes/kube/layouts/shortcodes/protocols-table.html new file mode 100644 index 000000000..2c2638b3a --- /dev/null +++ b/themes/kube/layouts/shortcodes/protocols-table.html @@ -0,0 +1,384 @@ + + + +
+
+ + +
+
+ + +
+
+ + +
+
+ + +
+
+ +
+ Showing {{ len $.Site.Data.outputs.protocols }} of {{ len $.Site.Data.outputs.protocols }} protocols +
+ + + + + + + + + + + + + + + {{ range $.Site.Data.outputs.protocols }} + + + + + + + + + + {{ end }} + +
ProtocolCategoryTargetCoreAuthorVersionDate
+ {{ .name }} + {{ with .description }} + i{{ . }} + {{ end }} + + {{ $categoryClass := "category-biochemical" }} + {{ if eq .category "Crystallization" }}{{ $categoryClass = "category-crystallization" }}{{ end }} + {{ if eq .category "Protein Production" }}{{ $categoryClass = "category-protein" }}{{ end }} + {{ if eq .category "Biophysical Assay" }}{{ $categoryClass = "category-biophysical" }}{{ end }} + {{ if eq .category "ADMET" }}{{ $categoryClass = "category-admet" }}{{ end }} + {{ if eq .category "Antiviral Assay" }}{{ $categoryClass = "category-antiviral" }}{{ end }} + {{ .category }} + {{ .target }}{{ range .cores }}{{ . }} {{ end }}{{ .author }}{{ with .version }}{{ . }}{{ end }}{{ .date }}
+ +